<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Scand J Trauma Resusc Emerg Med</journal-id><journal-id journal-id-type="iso-abbrev">Scand J Trauma Resusc Emerg Med</journal-id><journal-id journal-id-type="pmc-domain-id">707</journal-id><journal-id journal-id-type="pmc-domain">sjtrem</journal-id><journal-title-group><journal-title>Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine</journal-title></journal-title-group><issn pub-type="epub">1757-7241</issn><publisher><publisher-name>BMC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12232707</article-id><article-id pub-id-type="pmcid-ver">PMC12232707.1</article-id><article-id pub-id-type="pmcaid">12232707</article-id><article-id pub-id-type="pmcaiid">12232707</article-id><article-id pub-id-type="pmid">40619437</article-id><article-id pub-id-type="doi">10.1186/s13049-025-01438-8</article-id><article-id pub-id-type="publisher-id">1438</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Landiolol bolus application for tachycardic dysrhythmia in the prehospital EMS setting &#8211; An observational study of a novel concept</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" equal-contrib="yes"><name name-style="western"><surname>Eibensteiner</surname><given-names initials="F">Felix</given-names></name><address><email>felix.eibensteiner@meduniwien.ac.at</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Krammel</surname><given-names initials="M">Mario</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kornfehl</surname><given-names initials="A">Andrea</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Brock</surname><given-names initials="R">Roman</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Veigl</surname><given-names initials="C">Christoph</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Grassmann</surname><given-names initials="D">Daniel</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hamp</surname><given-names initials="T">Thomas</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Domanovits</surname><given-names initials="H">Hans</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sulzgruber</surname><given-names initials="P">Patrick</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Schnaubelt</surname><given-names initials="S">Sebastian</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05n3x4p02</institution-id><institution-id institution-id-type="GRID">grid.22937.3d</institution-id><institution-id institution-id-type="ISNI">0000 0000 9259 8492</institution-id><institution>Department of Emergency Medicine, </institution><institution>Medical University of Vienna, </institution></institution-wrap>Waehringer Guertel 18-20, Vienna, 1090 Austria </aff><aff id="Aff2"><label>2</label>Emergency Medical Service Vienna, Vienna, 1030 Austria </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05n3x4p02</institution-id><institution-id institution-id-type="GRID">grid.22937.3d</institution-id><institution-id institution-id-type="ISNI">0000 0000 9259 8492</institution-id><institution>Division of Cardiology, Department of Internal Medicine II, </institution><institution>Medical University of Vienna, </institution></institution-wrap>Vienna, 1090 Austria </aff></contrib-group><pub-date pub-type="epub"><day>6</day><month>7</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>33</volume><issue-id pub-id-type="pmc-issue-id">478383</issue-id><elocation-id>119</elocation-id><history><date date-type="received"><day>7</day><month>2</month><year>2025</year></date><date date-type="accepted"><day>27</day><month>6</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>06</day><month>07</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>07</day><month>07</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-07-08 11:25:24.683"><day>08</day><month>07</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="13049_2025_Article_1438.pdf"/><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Tachydysrhythmias are a challenging aspect of emergency medicine, with atrial fibrillation being the most common. Electrical cardioversion is recommended for hemodynamically unstable patients, while treatment varies according to the dysrhythmia subtype in others. Landiolol, a relatively new ultra-short-acting cardioselective beta-blocker, may be a promising option for prehospital use due to its advantageous pharmacological properties.</p></sec><sec><title>Methods</title><p id="Par2">This observational study included all cases of Landiolol bolus administration of the Emergency Medical Service (EMS) Vienna from 08/2023 until 06/2024. Data were extracted from EMS reports and hospital records. The primary endpoint was drug safety and adverse events. Secondary outcomes were the effect on hemodynamic and rate- and rhythm control.</p></sec><sec><title>Results</title><p id="Par3">We analysed reports of 111 patients having received push-dose Landiolol (median 74 [interquartile ranges (IQR) 62&#8211;81] years; 57% female; dosage median 20 [IQR 7&#8211;20] mg). Leading symptoms were palpitations (35%), dyspnoea (26%), and chest pain (18%), with atrial fibrillation as the most common dysrhythmia (64%). No allergic reactions, relevant bradycardias or cardiac arrests were detected immediately after Landiolol administration. In 59%, an improvement in patients&#8217; condition was reported. Rhythm control was achieved in 14%, and rate control in 44%. No effect was seen in 34%. The heart rate was significantly (median 170 [IQR 150&#8211;190] vs. median 123 [IQR 99 &#8722;&#8201;140] bpm; <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001) lower after drug administration. Phenylephrine administration with a probable causal relation to Landiolol was needed in four cases (3.6%). Overall, there was no relevant effect on mean arterial blood pressure (median 90 [IQR 80&#8211;105] vs. median 91 [IQR 77&#8211;101] mmHg; <italic toggle="yes">p</italic>&#8201;=&#8201;0.362).</p></sec><sec><title>Conclusion</title><p id="Par4">Push-dose Landiolol could be a conceivable future therapeutic option for tachydysrhythmia in the EMS setting. In particular, a high incidence of rate or rhythm control can be achieved. Utilization should be allocated to non-compensatory tachycardia only. Drug response and control groups with other drugs should be further investigated.</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1186/s13049-025-01438-8.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Landiolol</kwd><kwd>Betablocker</kwd><kwd>Dysrhythmia</kwd><kwd>EMS</kwd><kwd>Prehospital</kwd><kwd>Emergency</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Norwegian Air Ambulance Foundation 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par5">Tachydysrhythmias are a challenging condition that affect both prehospital and in-hospital emergency medicine. Atrial fibrillation is the most common dysrhythmia worldwide, affecting approximately 60&#160;million people [<xref ref-type="bibr" rid="CR1">1</xref>]. The incidence of supraventricular tachycardia is 2.25/1000 individuals, with women being affected more often than men [<xref ref-type="bibr" rid="CR2">2</xref>], and the incidence of ventricular dysrhythmia lies between 1-200/100,000 people [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>]. It is also known that up to 8% of patients with acute coronary syndrome develop ventricular dysrhythmia [<xref ref-type="bibr" rid="CR5">5</xref>]. Therefore, rapid and effective heart rate or rhythm control seems essential to prevent hemodynamic instability and reduce the risk of severe complications, such as acute heart failure, myocardial ischemia, cardiogenic shock, or cardiac arrest. The latest guidelines of the European Resuscitation Council (ERC) recommend a simple and pragmatic approach: In the event of hemodynamic instability, electrical cardioversion should be performed as quickly as possible. After that, further management varies depending on the subtype of tachycardia. In particular, &#946;-blockers are recommended for the frequently-occurring atrial fibrillation (AF) [<xref ref-type="bibr" rid="CR6">6</xref>]. Also in the latest guidelines of the European Society of Cardiology (ESC), rate control with &#946;-blockers or digoxin is recommended in hemodynamically stable AF, regardless of left ventricular function (LVEF), with particular reference to cardioselective &#946;-blockers. In unstable conditions, electrical cardioversion is recommended as first-line, but Landiolol or Amiodarone are emphasized as a second option, especially in critical illness [<xref ref-type="bibr" rid="CR7">7</xref>]. A study in American and British intensive care unit (ICU) patients compared different pharmacological methods of treating new-onset atrial fibrillation and showed a superiority of &#223;-blockers and Amiodarone over Digoxin and calcium channel blockers in terms of rhythm- or rate-control. No differences were found between &#223;-blockers and Amiodarone in terms of effectiveness, nor were there any differences in mortality [<xref ref-type="bibr" rid="CR8">8</xref>]. However, other evidence by Walkey et al. [<xref ref-type="bibr" rid="CR9">9</xref>] or Balik et al. [<xref ref-type="bibr" rid="CR10">10</xref>] pointed at a reduction in mortality when using &#223;-blockers compared to Amiodarone. Furthermore, the less favourable side effect profile of Amiodarone including thyroid-, hepatic-, and pulmonary dysfunction must be considered [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR11">11</xref>&#8211;<xref ref-type="bibr" rid="CR14">14</xref>]. Intravenous &#946;-blockers such as Metoprolol or esmolol are recommended therapeutic agents in acute tachydysrhythmia [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR15">15</xref>]. They exert their effects primarily through &#946;1-selective blockade, effectively reducing heart rate and myocardial oxygen demand [<xref ref-type="bibr" rid="CR16">16</xref>], though with a concomitant adverse effect on hemodynamics, particularly with Metoprolol [<xref ref-type="bibr" rid="CR17">17</xref>]. The use of these &#946;-blockers in the prehospital setting must be carefully considered as they may pose a risk in hemodynamically unstable patients. Moreover, the prehospital setting has a reduced availability and practicability of syringe pump.</p><p id="Par6">Landiolol, a newer ultrashort-acting cardioselective &#946;-blocker, has emerged as a promising alternative due to its favourable pharmacodynamic and pharmacokinetic profile. The older cardioselective &#223;1-blockers Metoprolol and esmolol each have a &#223;1:&#223;2-ratio of 2.3 and 43 [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>]. Landiolol is characterized by a clearly higher &#946;1-selectivity (&#223;1:&#223;2&#8201;=&#8201;255) [<xref ref-type="bibr" rid="CR20">20</xref>], a very short half-life of 2&#8211;4&#160;min [<xref ref-type="bibr" rid="CR21">21</xref>], and rapid onset of action within 1&#8211;3&#160;min as a bolus medication [<xref ref-type="bibr" rid="CR22">22</xref>], allowing for precise control of its therapeutic effects. In addition, it is not only available as a syringe pump formulation but also in ampoules for bolus use. These attributes make Landiolol particularly suitable for the prehospital use, where rapid and controlled heart rate reduction is necessary without the prolonged effects associated with traditional &#946;-blockers [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR24">24</xref>].</p><p id="Par7">Landiolol could represent a valuable addition to the prehospital management of tachydysrhythmias, expanding current treatment options. To the best of our knowledge, this study is the first to investigate the bolus administration of Landiolol in a prehospital emergency medicine setting, with a particular focus on evaluating safety and adverse events of bolus administration of Landiolol.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Study setting</title><p id="Par8">This analysis is part of a retrospective registry recording the use of Landiolol as a continuous or bolus medication in the in- and prehospital setting. In Austria, there is a physician-based emergency medical system. Two paramedics attend to all emergency calls, and if primarily indicated or needed later-on, emergency physicians traveling in an additional vehicle together with another paramedic are deployed as well. Previously, it was common practice for emergency physicians to achieve either rate- or rhythm- control with Metoprolol or Amiodarone in the prehospital setting in Vienna, as no other drugs were available. Since 08/2023, the ultra-short and fast-acting &#223;-blocker Landiolol was available as an alternative drug in the Emergency Medical Service (EMS) of Vienna. Prior to implementation, all emergency physicians were trained by means of lectures, information letters, and memory aids (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>), which are also continuously available in all emergency physician vehicles. Naturally, the decision which medication to use for the patients they treated was at all times left to the discretion of the emergency physicians. Recommendations for the use were provided via mnemonics (<italic toggle="yes">see</italic> Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>), but of course emergency doctors could also decide to use it off-label at their own responsibility. Subsequently, the EMS- and monitoring reports of all patients who had received Landiolol were extracted together with an information technologist from the database of the EMS Vienna. In addition, the discharge reports of the hospitalized patients were requested from the respective hospitals in order to obtain a follow-up from the prehospital to the in-hospital phase. In this way, all patient-related information such as vital signs, demographics, co-medication, adverse effects, etc. were collected and are represented in a descriptive manner. Available parameters varied widely, as there were ambulance missions where either more or fewer values were recorded during the treatment of the patient. For this reason, and to create homogeneity of the data, only the first and last values of the vital signs were used for our analysis. In many cases, vital signs were measured frequently according to the documentation but not synchronized into the EMS report, which is why the decision was made to use the first and last values. The quality of the patient- and mission-related parameters (anamnesis, pre-existing conditions, medication, duration of the dysrhythmia, etc.) were dependent on the quality of the documentation by the emergency physicians and paramedics and varied as well.</p><p id="Par9">
<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Preparation and dosage memory aid for Landiolol as a bolus medication for prehospital use. This provides a detailed description of the indications, preparation, and dosage and a translation into English on the right side. &#169; EMS Vienna 2024, reprinted with permission. Created in BioRender. Eibensteiner F. (2025)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e337" position="float" orientation="portrait" xlink:href="13049_2025_1438_Fig1_HTML.jpg"/></fig>
</p></sec><sec id="Sec4"><title>Study design</title><p id="Par10">This study was a retrospective analysis of the use of Landiolol as bolus administration in the EMS Vienna. The study was approved by the Ethics Committee of the Medical University of Vienna (No. 1442/2021) and adhered to the Declaration of Helsinki. Given the retrospective design and the use of anonymized data, the Ethics Committee granted a waiver of informed consent.</p></sec><sec id="Sec5"><title>Study population</title><p id="Par11">This retrospective analysis included all patients who received prehospital Landiolol as a bolus medication from the treating emergency physician in Vienna between 08/2023 and 06/2024. Due to the design of a retrospective observational study, the only inclusion criterion was the confirmed use of Landiolol for tachydysrhythmia.</p></sec><sec id="Sec6"><title>Outcome/endpoint</title><p id="Par12">The primary endpoint was the evaluation of the prehospital administration of Landiolol in terms of safety and adverse events (either allergic reaction with problems in breathing, swelling of airway and hypotension, or clinically relevant bradycardia&#8201;&lt;&#8201;50/min with/without treatment, or the requirement of catecholamines such as Phenylephrine for stabilizing unwanted blood pressure decrease, or cardiac arrest). The secondary endpoints were rhythm and rate control, as well as details of patients&#8217; hemodynamic and mortality.</p><p id="Par13">We also recorded whether there was a subjectively perceived improvement in heart rate, blood pressure, respiratory rate, oxygen saturation, and in the patient&#8217;s clinical condition. The subjectively perceived improvement was judged and documented by the emergency physician in the EMS report. We defined successful rate control as reducing the heart rate by more than 20% of the baseline heart rate at the time of hospital arrival. The 20% drop in heart rate was an arbitrary number, which is due to the lack of a uniform definition of successful rate control [<xref ref-type="bibr" rid="CR25">25</xref>]. Rhythm control was defined as a sustained sinus rhythm upon admission to the hospital. In addition, we analysed the further clinical courses of the respective patients in the hospital and after admission. A significant drop in blood pressure was defined as a decline of &gt;&#8201;20% from the initial value. Furthermore, data about additional antiarrhythmic drugs and the effects on heart rate and blood pressure were presented descriptively.</p></sec><sec id="Sec7"><title>Statistical analysis</title><p id="Par14">Numerical data are presented as median with interquartile range (IQR) dependent on their distribution. Categorical data are presented as absolute and relative frequencies. Differences in numerical data were analysed using the Wilcoxon rank-sum test. Changes in rhythm and the effect of Landiolol are presented as a Sankey diagram for better visualization. To compare the vital signs (blood pressure and heart rate) of Landiolol alone and Landiolol plus other antiarrhythmic drugs, data were compared using the Wilcoxon rank-sum test. Mortality data were visualized using a Kaplan-Meier curve. For data management and analyses, we used Microsoft Excel (Microsoft Corporation Redmond, United States of America) and International Business Machines Corporation (IBM) Statistical Package for the Social Sciences (SPSS) Statistics (Version 28, IBM Corporation). All tests were two-sided, and <italic toggle="yes">p</italic>-values of &lt;&#8201;0.05 were considered statistically significant.</p></sec></sec><sec id="Sec8"><title>Results</title><sec id="Sec9"><title>Study population</title><p id="Par15">A total of 111 patients with tachydysrhythmia were included in this retrospective observational study. Refer to Table&#160;<xref rid="Tab1" ref-type="table">1</xref> for basic demographics, comorbidities, and extended information on the ambulance missions.</p><p id="Par16">
<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Basic demographics, comorbidities, vital signs, respiration, leading symptom and first rhythm of the study population. Categorical data are presented as counts and percentages, and continuous data as medians and interquartile ranges (IQRs) iqr&#8201;=&#8201;interquartile range, bpm&#8201;=&#8201;beats per minute, &#176;c&#8201;=&#8201;degree celsius</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Table&#160;<xref rid="Tab1" ref-type="table">1</xref></th><th align="left" colspan="1" rowspan="1">Total</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">
<bold>Demographic</bold>
</td><td align="left" colspan="1" rowspan="1"><bold><italic toggle="yes">n</italic></bold>&#8201;<bold>=&#8201;111</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">Female sex, n (%)</td><td align="left" colspan="1" rowspan="1">63 (56.8)</td></tr><tr><td align="left" colspan="1" rowspan="1">Age, years (IQR)</td><td align="left" colspan="1" rowspan="1">74 (62&#8211;81)</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>Medical history</bold>
</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Hypertension, n (%)</td><td align="left" colspan="1" rowspan="1">75 (67.6)</td></tr><tr><td align="left" colspan="1" rowspan="1">Hyperlipidaemia, n (%)</td><td align="left" colspan="1" rowspan="1">56 (50.5)</td></tr><tr><td align="left" colspan="1" rowspan="1">Atrial fibrillation, n (%)</td><td align="left" colspan="1" rowspan="1">45 (40.5)</td></tr><tr><td align="left" colspan="1" rowspan="1">Diabetes, n (%)</td><td align="left" colspan="1" rowspan="1">34 (30.6)</td></tr><tr><td align="left" colspan="1" rowspan="1">Coronary artery disease, n (%)</td><td align="left" colspan="1" rowspan="1">32 (28.8)</td></tr><tr><td align="left" colspan="1" rowspan="1">Cardiomyopathy, n (%)</td><td align="left" colspan="1" rowspan="1">28 (25.2)</td></tr><tr><td align="left" colspan="1" rowspan="1">Chronic kidney disease, n (%)</td><td align="left" colspan="1" rowspan="1">22 (19.8)</td></tr><tr><td align="left" colspan="1" rowspan="1">Chronic obstructive pulmonary disease, n (%)</td><td align="left" colspan="1" rowspan="1">21 (18.9)</td></tr><tr><td align="left" colspan="1" rowspan="1">Malignant disease, n (%)</td><td align="left" colspan="1" rowspan="1">14 (12.6)</td></tr><tr><td align="left" colspan="1" rowspan="1">Other tachycardias, n (%)</td><td align="left" colspan="1" rowspan="1">13 (11.7)</td></tr><tr><td align="left" colspan="1" rowspan="1">Past stroke, n (%)</td><td align="left" colspan="1" rowspan="1">8 (7.2)</td></tr><tr><td align="left" colspan="1" rowspan="1">Chronic ethylism, n (%)</td><td align="left" colspan="1" rowspan="1">6 (5.4)</td></tr><tr><td align="left" colspan="1" rowspan="1">Asthma bronchiale, n (%)</td><td align="left" colspan="1" rowspan="1">4 (3.6)</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>Vital signs and respiration at initial assessment</bold>
</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Systolic blood pressure, mmHg (IQR)</td><td align="left" colspan="1" rowspan="1">120 (105&#8211;140)</td></tr><tr><td align="left" colspan="1" rowspan="1">Diastolic blood pressure, mmHg (IQR)</td><td align="left" colspan="1" rowspan="1">78 (65&#8211;90)</td></tr><tr><td align="left" colspan="1" rowspan="1">Mean arterial pressure, mmHg (IQR)</td><td align="left" colspan="1" rowspan="1">90 (80&#8211;105)</td></tr><tr><td align="left" colspan="1" rowspan="1">Heart rate, bpm (IQR)</td><td align="left" colspan="1" rowspan="1">170 (150&#8211;190)</td></tr><tr><td align="left" colspan="1" rowspan="1">Serum glucose, mmol/L (IQR)</td><td align="left" colspan="1" rowspan="1">149 (127&#8211;184)</td></tr><tr><td align="left" colspan="1" rowspan="1">Glasgow Coma Scale, points (IQR)</td><td align="left" colspan="1" rowspan="1">15 (15&#8211;15)</td></tr><tr><td align="left" colspan="1" rowspan="1">Temperature, &#176;C (IQR)</td><td align="left" colspan="1" rowspan="1">36.7 (36.2&#8211;37.1)</td></tr><tr><td align="left" colspan="1" rowspan="1">Respiratory rate, per minute (IQR)</td><td align="left" colspan="1" rowspan="1">19 (15&#8211;25)</td></tr><tr><td align="left" colspan="1" rowspan="1">Oxygen saturation, % (IQR)</td><td align="left" colspan="1" rowspan="1">96 (90&#8211;98)</td></tr><tr><td align="left" colspan="1" rowspan="1">Administered oxygen flow, L/min (IQR)</td><td align="left" colspan="1" rowspan="1">6 (3&#8211;9)</td></tr><tr><td align="left" colspan="1" rowspan="1">Overall oxygen demand, n (%)</td><td align="left" colspan="1" rowspan="1">43 (38.7)</td></tr><tr><td align="left" colspan="1" rowspan="1">Non-invasive ventilation by EMS, n (%)</td><td align="left" colspan="1" rowspan="1">4 (3.6)</td></tr><tr><td align="left" colspan="1" rowspan="1">Invasive ventilation by EMS, n (%)</td><td align="left" colspan="1" rowspan="1">3 (2.7)</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>Leading symptoms</bold>
</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Palpitations, n (%)</td><td align="left" colspan="1" rowspan="1">39 (35.1)</td></tr><tr><td align="left" colspan="1" rowspan="1">Dyspnoea, n (%)</td><td align="left" colspan="1" rowspan="1">29 (26.1)</td></tr><tr><td align="left" colspan="1" rowspan="1">Chest pain, n (%)</td><td align="left" colspan="1" rowspan="1">24 (21.6)</td></tr><tr><td align="left" colspan="1" rowspan="1">Collapse/Syncope, n (%)</td><td align="left" colspan="1" rowspan="1">7 (6.3)</td></tr><tr><td align="left" colspan="1" rowspan="1">Other, n (%)</td><td align="left" colspan="1" rowspan="1">33 (29.7)</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>First rhythm</bold>
</td><td align="left" colspan="1" rowspan="1">
<bold>Total</bold>
</td></tr><tr><td align="left" colspan="1" rowspan="1">Atrial fibrillation, n (%)</td><td align="left" colspan="1" rowspan="1">70 (63.1)</td></tr><tr><td align="left" colspan="1" rowspan="1">Atrial flutter, n (%)</td><td align="left" colspan="1" rowspan="1">15 (13.5)</td></tr><tr><td align="left" colspan="1" rowspan="1">Supraventricular tachycardia (no atrial fibrillation/flutter), n (%)</td><td align="left" colspan="1" rowspan="1">20 (18.0)</td></tr><tr><td align="left" colspan="1" rowspan="1">Ventricular tachycardia, n (%)</td><td align="left" colspan="1" rowspan="1">5 (4.5)</td></tr><tr><td align="left" colspan="1" rowspan="1">Unknown, n (%)</td><td align="left" colspan="1" rowspan="1">1 (1.8)</td></tr></tbody></table></table-wrap>
</p></sec><sec id="Sec10"><title>EMS missions</title><p id="Par17">Of the EMS missions, 70.3% took place during the day shifts (between 07:00&#160;h and 19:00&#160;h) and lasted an average of 01:29&#160;h. Drugs administered apart from Landiolol and cardioversion details are shown in Table&#160;<xref rid="Tab2" ref-type="table">2</xref>. Patients were accompanied to the hospital by the emergency physicians in 84.7% of cases (as opposed to by the emergency medical technicians alone).</p><p id="Par18">
<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table 2</label><caption><p>Information regarding EMS mission. Categorical data are presented as counts and percentages, and continuous data as medians and interquartile ranges (IQRs). EMS&#8201;=&#8201;Emergency medical service, iqr&#8201;=&#8201;interquartile range</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Table&#160;<xref rid="Tab2" ref-type="table">2</xref></th><th align="left" colspan="1" rowspan="1">Total</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">
<bold>Emergency medical service</bold>
</td><td align="left" colspan="1" rowspan="1"><bold><italic toggle="yes">n</italic></bold>&#8201;<bold>=&#8201;111</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">Duration of EMS mission, hh: mm (IQR)</td><td align="left" colspan="1" rowspan="1">01:29 (1:13&#8211;1:48)</td></tr><tr><td align="left" colspan="1" rowspan="1">Day shift EMS mission, n (%)</td><td align="left" colspan="1" rowspan="1">78 (70.3)</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>Medication/Therapy</bold>
</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Crystalloid fluids, n (%)</td><td align="left" colspan="1" rowspan="1">75 (69.4)</td></tr><tr><td align="left" colspan="1" rowspan="1">Amiodarone, n (%)</td><td align="left" colspan="1" rowspan="1">16 (14.4)</td></tr><tr><td align="left" colspan="1" rowspan="1">Adenosine, n (%)</td><td align="left" colspan="1" rowspan="1">12 (10.8)</td></tr><tr><td align="left" colspan="1" rowspan="1">Magnesium, n (%)</td><td align="left" colspan="1" rowspan="1">12 (10.8)</td></tr><tr><td align="left" colspan="1" rowspan="1">Phenylephrine, n (%)</td><td align="left" colspan="1" rowspan="1">13 (11.7)</td></tr><tr><td align="left" colspan="1" rowspan="1">Metoprolol, n (%)</td><td align="left" colspan="1" rowspan="1">10 (9.0)</td></tr><tr><td align="left" colspan="1" rowspan="1">Electrical cardioversion after Landiolol, n (%)</td><td align="left" colspan="1" rowspan="1">3 (2.7)</td></tr></tbody></table></table-wrap>
</p></sec><sec id="Sec11"><title>Outcomes</title><sec id="Sec1333"><title>Primary outcome: Safety and adverse events</title><p id="Par19">No adverse effects such as relevant bradycardia, allergic reactions or cardiac arrest were reported in direct connection with the application of Landiolol. In one patient, the ambulance report stated that sick sinus syndrome was suspected after the administration of Landiolol, with initial tachycardic atrial fibrillation and a brief bradycardia to 50/min.; however, this was not confirmed on further examination in the hospital. The maximum blood pressure reduction was reported with &#8722;&#8201;38 mmHg mean arterial pressure (MAP) (MAP from 122 to 84 mmHg) in one patient with tachycardic atrial fibrillation and exacerbated chronic obstructive pulmonary disease (COPD). In the initial assessment, this patient was clearly hypertensive and tachycardic in the context of his COPD exacerbation, probably also including cardiac decompensation. After treatment with cortisone, furosemide, and Landiolol, there was a reduction in heart rate and normalization of blood pressure, which was deemed a clinical improvement and not an adverse event, because the MAP was interpreted as normal at 84 mmHg. Overall, 13 patients required intravenous catecholamines during their prehospital treatment phase: Upon detailed review of the respective EMS reports, in four patients, the treating physician suggested a direct association between a drop in blood pressure and the administration of Landiolol, and Phenylephrine became necessary. In the other nine patients receiving catecholamines during the prehospital treatment phase, this was probably not causally related to Landiolol: In two cases, Phenylephrine had already been administered prior to Landiolol due to low blood pressure, and the remaining seven patients already had low blood pressure (MAP median 61 [IQR 58&#8211;65] mmHg) before Landiolol was administered and the Phenylephrine after Landiolol was suggested to have been necessary anyway. Five of these seven patients experienced a rate or rhythm control effect of Landiolol. Table <xref rid="MOESM2" ref-type="media">S1</xref> presents details about blood pressure and heart rate in patients who received catecholamines.</p></sec><sec id="Sec5551"><title>Secondary outcomes</title><sec id="Sec2221"><title>Mortality</title><p id="Par20">No patients died in the prehospital phase. A total of 15 (13.5%) admitted to hospital died in the hospital (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>). Three (20.0%) of these patients already required catecholamines for stabilization at the prehospital stage and two (13.3%) had a clinically significant drop in blood pressure documented by the emergency physician. Two (13.3%) patients were transferred to an intensive care unit or a normal ward, 7 (46.7%) to an intermediate care unit (IMC), and 4 (26.7%) to an outpatient clinic. Six patients died as a result of circulatory and respiratory failure, respectively. Three patients died as a consequence of sepsis, and one patient died as a result of mesenteric ischemia.</p><p id="Par21">
<fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>Kaplan-Meier Curve for in-hospital survival</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e758" position="float" orientation="portrait" xlink:href="13049_2025_1438_Fig2_HTML.jpg"/></fig>
</p></sec><sec id="Sec1555"><title>Effects of bolus Landiolol administration on rhythm and hemodynamics</title><p id="Par22">The median total dose of Landiolol was 20&#160;mg (IQR 7&#8211;20&#160;mg), which was usually administered fractionally (maximum overall dose: 40&#160;mg; minimum overall dose: 2&#160;mg). The EMS reports were assessed for documentation of the effect of Landiolol. Emergency physicians reported a positive clinical effect of Landiolol in 58.6% of cases (with 44.1% of rate control and 14.4% of rhythm control). In 34.2% of cases, no effect of Landiolol could be shown, and in 8 cases (7.2%), there was no respective documentation available. (Table&#160;<xref rid="Tab3" ref-type="table">3</xref> and Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>). In addition, we have categorized the reported effect according to the type of dysrhythmia, as shown in Table&#160;<xref rid="Tab3" ref-type="table">3</xref>. The predefined sustained successful rate control of more than 20% heart rate decrease from the initial measured heart rate to hospital handover was reached in 34 (30.6%) patients.</p><p id="Par23">
<table-wrap id="Tab3" position="float" orientation="portrait"><label>Table 3</label><caption><p>Subjective information from paramedics and emergency physicians about the effect of Landiolol on heart rate and blood pressure in total and divided in subgroups of different dysrhythmias. No effect&#8201;=&#8201;no effect of Landiolol whether on rate or rhythm, effect unknown&#8201;=&#8201;missing data on rate, rhythm or no effect, afib&#8201;=&#8201;atrial fibrillation, aflu&#8201;=&#8201;atrial flutter, svt&#8201;=&#8201;supraventricular tachycardia, vt&#8201;=&#8201;ventricular tachycardia. * the blood pressure drop occurred after Landiolol administration; a causal relationship is unclear</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Table&#160;<xref rid="Tab3" ref-type="table">3</xref></th><th align="left" colspan="1" rowspan="1">Total</th><th align="left" colspan="1" rowspan="1">AFib</th><th align="left" colspan="1" rowspan="1">AFlu</th><th align="left" colspan="1" rowspan="1">SVT</th><th align="left" colspan="1" rowspan="1">VT</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">
<bold>Emergency physicians&#180; report</bold>
</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#8201;=&#8201;111</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#8201;=&#8201;70</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#8201;=&#8201;15</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#8201;=&#8201;20</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#8201;=&#8201;5</td></tr><tr><td align="left" colspan="1" rowspan="1">Overall clinical improvement, n (%)</td><td char="." align="char" colspan="1" rowspan="1">65 (58.6)</td><td char="." align="char" colspan="1" rowspan="1">38 (54.3)</td><td align="left" colspan="1" rowspan="1">10 (66.7)</td><td char="." align="char" colspan="1" rowspan="1">13 (65.0)</td><td align="left" colspan="1" rowspan="1">4 (80.0)</td></tr><tr><td align="left" colspan="1" rowspan="1">Rate control, n (%)</td><td char="." align="char" colspan="1" rowspan="1">49 (44.1)</td><td char="." align="char" colspan="1" rowspan="1">34 (48.6)</td><td align="left" colspan="1" rowspan="1">9 (60.0)</td><td char="." align="char" colspan="1" rowspan="1">6 (30.0)</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">Rhythm control, n (%)</td><td char="." align="char" colspan="1" rowspan="1">16 (14.4)</td><td char="." align="char" colspan="1" rowspan="1">4 (5.7)</td><td align="left" colspan="1" rowspan="1">1 (6.7)</td><td char="." align="char" colspan="1" rowspan="1">7 (35.0)</td><td align="left" colspan="1" rowspan="1">4 (80.0)</td></tr><tr><td align="left" colspan="1" rowspan="1">No effect, n (%)</td><td char="." align="char" colspan="1" rowspan="1">38 (34.2)</td><td char="." align="char" colspan="1" rowspan="1">26 (37.1)</td><td align="left" colspan="1" rowspan="1">5 (33.3)</td><td char="." align="char" colspan="1" rowspan="1">5 (25.0)</td><td align="left" colspan="1" rowspan="1">1 (20.0)</td></tr><tr><td align="left" colspan="1" rowspan="1">Effect unknown, n (%)</td><td char="." align="char" colspan="1" rowspan="1">8 (7.2)</td><td char="." align="char" colspan="1" rowspan="1">6 (8.6)</td><td align="left" colspan="1" rowspan="1">-</td><td char="." align="char" colspan="1" rowspan="1">2 (10.0)</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">Blood pressure drop, n (%)*</td><td char="." align="char" colspan="1" rowspan="1">7 (6.3)</td><td char="." align="char" colspan="1" rowspan="1">4 (5.7)</td><td align="left" colspan="1" rowspan="1">1 (6.7)</td><td char="." align="char" colspan="1" rowspan="1">2 (10.0)</td><td align="left" colspan="1" rowspan="1">-</td></tr></tbody></table></table-wrap>
</p><p id="Par24">
<fig id="Fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><p>Overall effect of Landiolol on the heart rhythm after bolus application presented in a Sankey diagram</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e924" position="float" orientation="portrait" xlink:href="13049_2025_1438_Fig3_HTML.jpg"/></fig>
</p><p id="Par25">
<table-wrap id="Tab4" position="float" orientation="portrait"><label>Table 4</label><caption><p>Vital signs comparing initial vs. last parameters. Continuous data are presented as medians and interquartile ranges (IQRs)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Table&#160;<xref rid="Tab4" ref-type="table">4</xref></th><th align="left" colspan="2" rowspan="1">Initial vital signs</th><th align="left" colspan="1" rowspan="1">Last vital signs</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">p</italic>-value</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Heart rate, bpm (IQR)</td><td align="left" colspan="2" rowspan="1">170 (150&#8211;190)</td><td align="left" colspan="1" rowspan="1">123 (99&#8211;140)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Systolic blood pressure, mmHg (IQR)</td><td align="left" colspan="2" rowspan="1">120 (105&#8211;140)</td><td align="left" colspan="1" rowspan="1">121 (102&#8211;137)</td><td align="left" colspan="1" rowspan="1">0.741</td></tr><tr><td align="left" colspan="1" rowspan="1">Diastolic blood pressure, mmHg (IQR)</td><td align="left" colspan="2" rowspan="1">78 (65&#8211;90)</td><td align="left" colspan="1" rowspan="1">76 (65&#8211;85)</td><td align="left" colspan="1" rowspan="1">0.181</td></tr><tr><td align="left" colspan="1" rowspan="1">Mean arterial blood pressure, mmHg (IQR)</td><td align="left" colspan="2" rowspan="1">90 (80&#8211;105)</td><td align="left" colspan="1" rowspan="1">91 (77&#8211;101)</td><td align="left" colspan="1" rowspan="1">0.362</td></tr><tr><td align="left" colspan="1" rowspan="1">Respiratory rate, per minute (IQR)</td><td align="left" colspan="2" rowspan="1">19 (15&#8211;25)</td><td align="left" colspan="1" rowspan="1">16 (14&#8211;21)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Transcutaneous xxygen saturation (IQR)</td><td align="left" colspan="2" rowspan="1">93&#8201;&#177;&#8201;8</td><td align="left" colspan="1" rowspan="1">95&#8201;&#177;&#8201;3</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr></tbody></table></table-wrap>
</p><p id="Par26">The initial heart rate compared to the last heart rate in the ambulance showed a significant difference (median 170&#160;bpm vs. 123&#160;bpm, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001). Furthermore, the transcutaneous peripheral capillary oxygen saturation (SpO2) (median 96 [IQR 90&#8211;98]% vs. median 96 [IQR 94&#8211;98]%, p 0.003) and the respiratory rate (median 19/min vs. 16/min, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001) were significantly lower after Landiolol application. the initial systolic, diastolic, and mean blood pressure showed no significant differences before and after the application (Table&#160;<xref rid="Tab4" ref-type="table">4</xref>). However, 9% (<italic toggle="yes">n</italic>&#8201;=&#8201;10) of patients experienced a drop in mean arterial pressure of &gt;&#8201;20% from baseline. these 10 patients received a median dose of 17 (IQR 7&#8211;22) Mg landiolol, none of them required phenylephrine, and two patients received Metoprolol after administration of Landiolol but no further antiarrhythmic drugs. Details about objective changes in blood pressure and heart rate are shown in tables&#160;<xref rid="Tab5" ref-type="table">5</xref>, and more data are presented in Table <xref rid="MOESM2" ref-type="media">S2</xref> and figure <xref rid="MOESM2" ref-type="media">S1</xref>. Data about changes in blood pressure and heart rate in patients categorized according to the dysrhythmia subtype (atrial fibrillation, atrial flutter, supraventricular tachycardia, ventricular tachycardia) are presented in Table <xref rid="MOESM2" ref-type="media">S3</xref></p><p id="Par27">
<table-wrap id="Tab5" position="float" orientation="portrait"><label>Table 5</label><caption><p>Detailed information about heart rate and blood pressure changes. Categorical data are presented as counts and percentages, and continuous data as medians and interquartile ranges (IQRs). Bpm&#8201;=&#8201;beats per minute</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Table&#160;<xref rid="Tab5" ref-type="table">5</xref></th><th align="left" colspan="2" rowspan="1"/></tr></thead><tbody><tr><td align="left" colspan="2" rowspan="1">
<bold>Heart rate decrease from initial to last measurement</bold>
</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="2" rowspan="1">Heart rate decrease, &#916;bpm (IQR)</td><td align="left" colspan="1" rowspan="1">-40 (-17&#8211; -75)</td></tr><tr><td align="left" colspan="2" rowspan="1">Heart rate decrease&#8201;&gt;&#8201;20%, n (%)</td><td align="left" colspan="1" rowspan="1">69 (62.2)</td></tr><tr><td align="left" colspan="2" rowspan="1">Heart rate&#8201;&lt;&#8201;110&#160;bpm, n (%)</td><td align="left" colspan="1" rowspan="1">44 (39.6)</td></tr><tr><td align="left" colspan="2" rowspan="1">
<bold>Blood pressure changes from initial to last measurement</bold>
</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="2" rowspan="1">Systolic blood pressure decrease, &#916;mmHg (IQR)</td><td align="left" colspan="1" rowspan="1">-3 (-13&#8211;16)</td></tr><tr><td align="left" colspan="2" rowspan="1">Diastolic blood pressure decrease, &#916;mmHg (IQR)</td><td align="left" colspan="1" rowspan="1">-2 (-12&#8211;8)</td></tr><tr><td align="left" colspan="2" rowspan="1">Mean arterial blood pressure decrease, &#916;mmHg (IQR)</td><td align="left" colspan="1" rowspan="1">-0.2 (-12&#8211;8)</td></tr><tr><td align="left" colspan="2" rowspan="1">Mean arterial blood pressure drop&#8201;&gt;&#8201;20%, n (%)</td><td align="left" colspan="1" rowspan="1">10 (9.0)</td></tr></tbody></table></table-wrap>
</p></sec><sec id="Sec1666"><title>Antiarrhythmic drugs in addition to Landiolol</title><p id="Par28">A total of 24 patients received another antiarrhythmic medication in addition to Landiolol. Two (1.8%) received both Metoprolol and Amiodarone, eight (7.2%) received only Metoprolol, and 14 (12.6%) received only Amiodarone in addition to Landiolol. Of the patients who received Metoprolol, eight received a single dose of 5&#160;mg, one patient received 7&#160;mg, and another received 10&#160;mg. Five patients received 150&#160;mg of Amiodarone, nine patients received 300&#160;mg, and no information on the dosage was available for two patients.</p><p id="Par29">The chief complaints experienced by the patients who received additional antiarrhythmic drugs were palpitations in nine cases, dyspnoea in five cases, chest pain in two, syncope in one case, and various other symptoms in nine cases. Data on the effect of antiarrhythmic drugs categorized by type of dysrhythmia are shown in Table&#160;<xref rid="Tab6" ref-type="table">6</xref>.</p><p id="Par30">
<table-wrap id="Tab6" position="float" orientation="portrait"><label>Table 6</label><caption><p>Detailed information about the effect of antiarrhythmic drugs and the effect on heart rate and blood pressure, as well as the dose of administered landiolol. Categorical data are presented as counts and percentages, and continuous data as medians and interquartile ranges (IQRs). Bpm&#8201;=&#8201;beats per minute, hr&#8201;=&#8201;heart rate, map&#8201;=&#8201;mean arterial pressure</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Amiodarone +/- Metoprolol (<italic toggle="yes">n</italic>&#8201;=&#8201;24)</th><th align="left" colspan="1" rowspan="1">Initial HR,<break/>bpm (IQR)</th><th align="left" colspan="1" rowspan="1">Last HR,<break/>bpm (IQR)</th><th align="left" colspan="1" rowspan="1">Initial MAP,<break/>mmHg (IQR)</th><th align="left" colspan="1" rowspan="1">Last MAP,<break/>mmHg (IQR)</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Atrial fibrillation (<italic toggle="yes">n</italic>&#8201;=&#8201;18)</td><td align="left" colspan="1" rowspan="1">170 (150&#8211;196)</td><td align="left" colspan="1" rowspan="1">130 (115&#8211;156)</td><td align="left" colspan="1" rowspan="1">92 (85&#8211;101)</td><td align="left" colspan="1" rowspan="1">92 (77&#8211;100)</td></tr><tr><td align="left" colspan="1" rowspan="1">Atrial flutter (<italic toggle="yes">n</italic>&#8201;=&#8201;5)</td><td align="left" colspan="1" rowspan="1">162 (136&#8211;192)</td><td align="left" colspan="1" rowspan="1">104 (96&#8211;104)</td><td align="left" colspan="1" rowspan="1">85 (81&#8211;92)</td><td align="left" colspan="1" rowspan="1">89 (86&#8211;91)</td></tr><tr><td align="left" colspan="1" rowspan="1">Supraventricular tachycardia (<italic toggle="yes">n</italic>&#8201;=&#8201;0)</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">Ventricular tachycardia (<italic toggle="yes">n</italic>&#8201;=&#8201;1)</td><td align="left" colspan="1" rowspan="1">112</td><td align="left" colspan="1" rowspan="1">102</td><td align="left" colspan="1" rowspan="1">106</td><td align="left" colspan="1" rowspan="1">92</td></tr></tbody></table><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">
<bold>Amiodarone +/- Metoprolol (</bold>
<bold><italic toggle="yes">n</italic></bold>
<bold>&#8201;=&#8201;24)</bold>
</th><th align="left" colspan="1" rowspan="1"><bold>Rate control</bold>,<break/>
<bold>n (%)</bold>
</th><th align="left" colspan="1" rowspan="1"><bold>Rhythm control</bold>,<break/>
<bold>n (%)</bold>
</th><th align="left" colspan="1" rowspan="1"><bold>No effect</bold>,<break/>
<bold>n (%)</bold>
</th><th align="left" colspan="1" rowspan="1"><bold>Landiolol dose</bold>,<break/>
<bold>mg (IQR)</bold>
</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Atrial fibrillation (<italic toggle="yes">n</italic>&#8201;=&#8201;18)</td><td align="left" colspan="1" rowspan="1">5 (27.8)</td><td align="left" colspan="1" rowspan="1">-0 (0.0)</td><td align="left" colspan="1" rowspan="1">11 (61.1)</td><td align="left" colspan="1" rowspan="1">20 (16&#8211;22)</td></tr><tr><td align="left" colspan="1" rowspan="1">Atrial flutter (<italic toggle="yes">n</italic>&#8201;=&#8201;5)</td><td align="left" colspan="1" rowspan="1">2 (40.0)</td><td align="left" colspan="1" rowspan="1">0 (0.0)</td><td align="left" colspan="1" rowspan="1">3 (60%)</td><td align="left" colspan="1" rowspan="1">20 (14&#8211;20)</td></tr><tr><td align="left" colspan="1" rowspan="1">Supraventricular tachycardia (<italic toggle="yes">n</italic>&#8201;=&#8201;0)</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">Ventricular tachycardia (<italic toggle="yes">n</italic>&#8201;=&#8201;1)</td><td align="left" colspan="1" rowspan="1">0</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">0</td><td align="left" colspan="1" rowspan="1">20</td></tr></tbody></table></table-wrap>
</p><p id="Par31">A total of eight of the 24 patients who received additional antiarrhythmic drugs showed documented improvements: Rate control was achieved in seven patients and rhythm control in one patient. A significant reduction in blood pressure was reported in three patients. Three of these patients required intravenous catecholamines during EMS care. Only 2 of the patients had a drop in blood pressure of &gt;&#8201;20 mmHg from baseline.</p><p id="Par32">Of the patients receiving Landiolol as their only antiarrhythmic drug compared to Landiolol plus other antiarrhythmic drugs, 65.5% vs. 33.3% showed a clinical improvement (48.3% vs. 29.2% rate control and 17.2% vs. 4.2% rhythm control). The addition of Amiodarone and Metoprolol resulted in a significant reduction in heart rate but no significant difference in blood pressure (Table&#160;<xref rid="Tab7" ref-type="table">7</xref>). When comparing heart rate and blood pressure at baseline and shortly before hospital admission, no significant differences were found between the Landiolol-only group and the Landiolol plus other antiarrhythmic drugs group (Table <xref rid="MOESM2" ref-type="media">S4</xref>).</p><p id="Par33">
<table-wrap id="Tab7" position="float" orientation="portrait"><label>Table 7</label><caption><p>Effect of Amiodarone+/- Metoprolol in patients who received them in addition to landiolol. Continuous data are presented as medians and interquartile ranges (IQRs)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="2" rowspan="1">Table&#160;<xref rid="Tab7" ref-type="table">7</xref></th><th align="left" colspan="3" rowspan="1"/></tr><tr><th align="left" colspan="1" rowspan="1">Amiodarone +/- Metoprolol (<italic toggle="yes">n</italic>&#8201;=&#8201;24)</th><th align="left" colspan="2" rowspan="1">Initial vital signs</th><th align="left" colspan="1" rowspan="1">Last vital signs</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">p</italic>-value</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Heart rate, bpm (IQR)</td><td align="left" colspan="2" rowspan="1">170 (150&#8211;191)</td><td align="left" colspan="1" rowspan="1">125 (102&#8211;155)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Systolic blood pressure, mmHg (IQR)</td><td align="left" colspan="2" rowspan="1">126 (108&#8211;140)</td><td align="left" colspan="1" rowspan="1">120 (107&#8211;136)</td><td align="left" colspan="1" rowspan="1">0.145</td></tr><tr><td align="left" colspan="1" rowspan="1">Diastolic blood pressure, mmHg (IQR)</td><td align="left" colspan="2" rowspan="1">75 (69&#8211;91)</td><td align="left" colspan="1" rowspan="1">76 (68&#8211;81)</td><td align="left" colspan="1" rowspan="1">0.144</td></tr><tr><td align="left" colspan="1" rowspan="1">Mean arterial blood pressure, mmHg (IQR)</td><td align="left" colspan="2" rowspan="1">91 (85&#8211;100)</td><td align="left" colspan="1" rowspan="1">92 (81&#8211;98)</td><td align="left" colspan="1" rowspan="1">0.145</td></tr></tbody></table></table-wrap>
</p></sec><sec id="Sec78991"><title>In-hospital course and treatment</title><p id="Par34">In 48.6% of cases, patients were transferred to an intermediate care unit, 34.2% to an emergency department, and 12.6% to an intensive care unit. Using medical records and detailed medical histories, it was possible to determine that 33 (29.7%) of the patients had already been taking anticoagulants, and 51 (45.9%) oral &#223;-blockers. Further detailed information on changes in heart rate and blood pressure throughout the observational period given in Table <xref rid="MOESM2" ref-type="media">S5</xref>. A review of the laboratory results at hospital admission showed that the electrolytes were largely within the normal range. Median lactate was slightly elevated at 2.3 (IQR 1.60&#8211;3.40) mmol/L (threshold 1.8 mmol/L). In terms of infection, there was a slight increase in leukocytes with normal C-reactive protein. Among the cardiac enzymes, median troponin T was 32.50 (IQR 19.75&#8211;65.75) ng/L and median pro-brain natriuretic peptide was 1535 (IQR 516&#8211;4323) ng/L (Table <xref rid="MOESM2" ref-type="media">S6</xref>).</p><p id="Par35">The different heart rhythms and the various changes in rhythm over the observational period from first EMS contact to hospitalization and then hospital discharge are depicted in Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>. More than half of the patients (56.8%) were discharged with a sinus rhythm. Due to missing documentation in the hospital discharge letters, the discharge rhythm could not be determined in 28.8% (<italic toggle="yes">n</italic>&#8201;=&#8201;32) of the patients. It is noteworthy that the 16 deceased patients are also included in the 32 patients with an unclear discharge rhythm. 13 (11.7%) were discharged with a rate-controlled atrial fibrillation. The median length of stay in hospital was two days (IQR 0&#8211;10 days). 28.8% of all patients were discharged on the same day.</p><p id="Par36">
<fig id="Fig4" position="float" orientation="portrait"><label>Fig. 4</label><caption><p>Sankey diagram to help understand the different heart rhythms over the course of time during the observation of patients. AFib EMS&#8201;=&#8201;Atrial fibrillation at first EMS contact; AFlu EMS&#8201;=&#8201;Atrial flutter at first EMS contact; SVT EMS&#8201;=&#8201;Supraventricular tachycardia at first EMS contact. Unknown EMS&#8201;=&#8201;Defined as an unknown or not described rhythm at first EMS contact. VT EMS&#8201;=&#8201;Ventricular tachycardia at first EMS contact. PM hospital&#8201;=&#8201;Pacemaker rhythm at hospital admission The same definitions as for the EMS also apply to hospital stay and hospital discharge</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e1445" position="float" orientation="portrait" xlink:href="13049_2025_1438_Fig4_HTML.jpg"/></fig>
</p><p id="Par37">During the hospital stay, the most commonly used antiarrhythmic drug of choice was Amiodarone (22 cases or 19.8%), followed by &#223;-blockers such as Bisoprolol or Metoprolol in 22 (18.0%) of cases. Landiolol was used twice (1.8%) as a bolus and once (0.9%) as a syringe pump-medication in hospital. In 12 (10.8%) patients, spontaneous conversion to sinus rhythm occurred. Thirteen (11.7%) patients underwent electrical cardioversion (eCV) in the hospital. Of these, 84.6% (<italic toggle="yes">n</italic>&#8201;=&#8201;11) converted to sinus rhythm after eCV. In 16.2% (<italic toggle="yes">n</italic>&#8201;=&#8201;18) of the cases, drug-induced rhythm control or rate control was performed (Table&#160;<xref rid="Tab8" ref-type="table">8</xref>).</p><p id="Par38">
<table-wrap id="Tab8" position="float" orientation="portrait"><label>Table 8</label><caption><p>Therapeutic approach during the hospital stay and the effect on rhythm or rate. Categorical data are presented as counts and percentages, and continuous data as medians and interquartile ranges (IQRs). eCV&#8201;=&#8201;electrical cardioversion. *administered via syringe pump</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Table&#160;<xref rid="Tab8" ref-type="table">8</xref></th><th align="left" colspan="1" rowspan="1"/></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">
<bold>Therapy during the hospital stay</bold>
</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Amiodarone, n (%)</td><td align="left" colspan="1" rowspan="1">22 (19.8)</td></tr><tr><td align="left" colspan="1" rowspan="1">Beta blockers (other than Landiolol), n (%)</td><td align="left" colspan="1" rowspan="1">20 (18.0)</td></tr><tr><td align="left" colspan="1" rowspan="1">Electrical cardioversion attempt, n (%)</td><td align="left" colspan="1" rowspan="1">13 (11.7)</td></tr><tr><td align="left" colspan="1" rowspan="1">Digitalis, n (%)</td><td align="left" colspan="1" rowspan="1">10 (9.0)</td></tr><tr><td align="left" colspan="1" rowspan="1">Adenosine, n (%)</td><td align="left" colspan="1" rowspan="1">4 (3.6)</td></tr><tr><td align="left" colspan="1" rowspan="1">Landiolol bolus, n (%)</td><td align="left" colspan="1" rowspan="1">2 (1.8)</td></tr><tr><td align="left" colspan="1" rowspan="1">Landiolol as continuous medication, n (%)*</td><td align="left" colspan="1" rowspan="1">1 (0.9)</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>Effect of therapy</bold>
</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Rhythm control, n (%)</td><td align="left" colspan="1" rowspan="1">18 (16.2)</td></tr><tr><td align="left" colspan="1" rowspan="1">Rate control, n (%)</td><td align="left" colspan="1" rowspan="1">18 (16.2)</td></tr><tr><td align="left" colspan="1" rowspan="1">Spontaneous rhythm control, n (%)</td><td align="left" colspan="1" rowspan="1">12 (10.8)</td></tr><tr><td align="left" colspan="1" rowspan="1">Sinus rhythm after eCV, n (%)</td><td align="left" colspan="1" rowspan="1">11 (84.6)</td></tr></tbody></table></table-wrap>
</p></sec></sec></sec></sec><sec id="Sec12"><title>Discussion</title><p id="Par39">This study was, according to the best of our knowledge, the first to evaluate the use of bolus Landiolol in the prehospital setting. In our prehospital screened unselected cohort with tachydysrhythmias, we were able to show that there were no adverse effects such as allergy, bradycardia or cardiac arrest. A small proportion (<italic toggle="yes">n</italic>&#8201;=&#8201;4, 3.6%) required catecholamines with a potential causal relation to Landiolol. We were able to show that 59% of patients had a clinical improvement of their condition in terms of rate (44%) or rhythm control (14%). Also, there was a significant reduction in heart rate without major relevant overall effects on blood pressure.</p><sec id="Sec7771"><title>Rhythm and rate control</title><p id="Par40">One advantage of Landiolol may be in the treatment of symptomatic atrial fibrillation, where literature claim that the aim is to restore sinus rhythm as quick as possible [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR27">27</xref>]. In these cases, rhythm control can been achieved in up to 75% of ICU patients with Landiolol [<xref ref-type="bibr" rid="CR28">28</xref>]. One possible reason for the lower rhythm-controlling effect of Landiolol in our study could be the different collective of acutely prehospitally critically ill patients. On the other hand, our documented successful heart rate reduction of 44% was higher than the actual calculated predefined rate control (heart rate decrease&#8201;&gt;&#8201;20% between initial and last heart rate) of 30.6% (<italic toggle="yes">n</italic>&#8201;=&#8201;34). The difference could be explained by the fact that Landiolol has a rapid onset of action, but also a more rapid loss of action if it is not re-administered at regular intervals [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR29">29</xref>]. With an average EMS response time of 1&#160;h and 30&#160;min, the lower amount of effectively sustained rate control could be explained by a decreasing effect of the Landiolol bolus, due to the short-half life time of Landiolol. Furthermore, rhythm control is not always a desirable goal, especially in patients with atrial fibrillation or flutter, because the risk of thromboembolic events can be significantly increased [<xref ref-type="bibr" rid="CR30">30</xref>]. Also, particularly in the prehospital setting, it is not always possible to determine the exact onset of the arrhythmia or to ensure adequate anticoagulation. However, we observed a relatively low rhythm conversion rate (five patients with atrial fibrillation and flutter). The primary objective of Landiolol is, of course, rate control. However, in the future, it may also be necessary to consider the &#8220;risk&#8221; of sinus conversion in patients with atrial fibrillation/flutter, rather than merely controlling heart rate. This would require early risk assessment, particularly for pre-hospital use, in order to reduce the risk of thromboembolism. Also, it has been shown that early treatment, especially in the prehospital setting, is associated with shorter hospital stays and lower mortality rates [<xref ref-type="bibr" rid="CR31">31</xref>]. The resulting risk / benefit ratio in patients that are considered clearly critically ill is probably easier to assess (in an emergency setting, also electrical cardioversion does not take thromboembolic risk into account) than for patients in the &#8220;grey&#8221; zone between stabile and critical, and where symptom control and stopping a fast-progressing vitious circle of tachydysrhythmia and reduced cardiac output early on is of importance for modern prehospital emergency medicine. Waiting for patients to deteriorate in order to then consider them as &#8220;critical enough&#8221; to administer medication cannot be an option.</p><p id="Par41">Similar to another study of bolus Landiolol in a medical ICU cohort, it was shown that Landiolol had no effect on tachycardia in about 1/3 of the applications (34.2% prehospital cohort vs. 32.7% ICU-cohort) [<xref ref-type="bibr" rid="CR24">24</xref>]. It is therefore likely that some patients are non-responders for reasons that are not yet known [<xref ref-type="bibr" rid="CR24">24</xref>]. These patients should be examined more thoroughly to find possible non-responder reasons.</p></sec><sec id="Sec8991"><title>Hemodynamics</title><p id="Par42">Only a small proportion (9%) of applications resulted in a reported reduction in blood pressure. This rate of blood pressure reduction was lower than in a large meta-analysis of over 1600 patients with reduced LVEF receiving Landiolol for supraventricular tachycardia, where a significant blood pressure reduction was documented in 15% of patients. Nevertheless, in comparison to other antiarrhythmic drugs, no distinction was observed in the incidence of hypotension, and Landiolol administration was only interrupted in 6% of cases. The most prevalent cause of hypotension was identified as a dose-dependent effect of Landiolol [<xref ref-type="bibr" rid="CR32">32</xref>]. Push dose catecholamines were administered in 12% (<italic toggle="yes">n</italic>&#8201;=&#8201;13). Because of the decrease in blood pressure associated with Landiolol mentioned by the emergency physicians, the catecholamine administrations were required as a side effect of Landiolol in four patients, two patients received catecholamines prior to Landiolol administration and for another reason in the other patients (e.g., prior low blood pressure), and therefore the administration of Phenylephrine cannot be linked directly to the administration of Landiolol but can also not be completely ruled out. So far, a large meta-analysis assessing &#223;-blockers as Propranolol, Esmolol, Carvedilol, Metoprolol, Labetalol and Landiolol found no difference compared to standard-of-care/placebo in catecholamine requirements when beta-blockers were given to critically ill patients [<xref ref-type="bibr" rid="CR33">33</xref>]. In a recent study of septic patients with tachycardia and Landiolol use, it was shown that a significantly higher dose of norepinephrine was required in the Landiolol group than in the standard of care group [<xref ref-type="bibr" rid="CR34">34</xref>]. These data were confirmed in the very recent Landi-SEP study, which also showed that more catecholamines were required in the early phase than in the control group, but these results were not significantly different [<xref ref-type="bibr" rid="CR35">35</xref>]. It has previously been highlighted that patients presenting with septic shock require a distinct approach to management, given the necessity for tachycardia and, in some cases, controlled fluid therapy [<xref ref-type="bibr" rid="CR36">36</xref>]. Nevertheless, this is not feasible without hemodynamic monitoring, which was not conducted in the aforementioned studies [<xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR35">35</xref>]. In the future, a markedly more differentiated approach will be necessary to identify patients with an appropriate indication, not only in the context of sepsis. In particular, with regard to prehospital patients, where hemodynamic monitoring is only possible to a very limited extent. Contrary data could be shown, for example, in smaller studies on coronarvirus disease 2019 (COVID-19) patients with tachycardic atrial fibrillation or patients with acute heart failure, where a decrease in catecholamine requirement was shown after the start of Landiolol [<xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR38">38</xref>]. Overall, the data for therapy with continuous Landiolol are inconclusive, so it would of course be interesting to see whether the catecholamine requirement changes after administration of a Landiolol bolus compared to a randomized group. This is particularly important in critically ill patients in the prehospital setting, where monitoring is more limited than in most studies conducted in the ICU. In a study by Schnaubelt et al. which also examined bolus Landiolol in ICU patients, a significantly increased catecholamine requirement was identified, particularly in patients with atrial fibrillation and patients with a significant volume overload [<xref ref-type="bibr" rid="CR24">24</xref>].</p></sec><sec id="Sec1099"><title>Tachydysrhythmia in the prehospital setting</title><p id="Par43">Structured literature about treatment of prehospital tachydysrhythmia with &#223;-blockers is rare. A study about tachydysrhythmia prevalence in emergency departments showed a comparable prevalence of atrial fibrillation with 67% (63% in our collective) [<xref ref-type="bibr" rid="CR39">39</xref>]. An Australian study examined the treatment of supraventricular tachycardia in more than 900 patients. The most common therapeutic intervention was the Valsalva manoeuvre, which was performed in 24% of patients, followed by intravenous verapamil in 5% of patients. This study showed successful rate control in 86.6% of patients, but also a high rate of hypotension in 31.6%. Beta-blockers were not used in this study [<xref ref-type="bibr" rid="CR40">40</xref>]. A large very recent American study of over 4800 patients with atrial fibrillation investigated the outcome of patients who received rate-controlling medication in the prehospital setting. This study showed that these patients were more likely to be discharged from the emergency department and had lower mortality rates than patients who did not receive rate-controlling medication. Patients on prehospital medications achieved the target of heart rate&#8201;&lt;&#8201;110/min in approximately 41%, which is comparable to our data of 39.6%. It was also interesting to note that the treated patients had significantly more hypotensive episodes, but in three quarters of the cases this hypotension had resolved by the time of transfer to the emergency department. In line with this, 69.2% of our patients showed an independent recovery of blood pressure without necessity of medication. However, in this study too, &#223;-blockers were used in only 5.4% of all patients and &gt;&#8201;80% received diltiazem [<xref ref-type="bibr" rid="CR41">41</xref>]. With regard to the study by Fornage et al. it would certainly be appropriate to conduct further studies with a detailed investigation of cardioselective &#946;-blockers, which have a significantly better side-effect profile than, for example, calcium channel blockers [<xref ref-type="bibr" rid="CR41">41</xref>]. Another study investigated the effect of continuous versus bolus diltiazem in a preclinical setting. It was shown that the rate control effect was equally good and that repeated administration of bolus diltiazem was not required more often [<xref ref-type="bibr" rid="CR42">42</xref>]. In view of the easier application of bolus doses, even with &#946;-blockers, it would be interesting to investigate a similar effect with cardioselective &#946;-blockers such as Landiolol or esmolol in the prehospital setting.</p><p id="Par44">Overall, AF is one of the most common dysrhythmias and therefore has a relevant impact on emergency services. An Australian study showed that 1% of all ambulance calls were for AF and &gt;&#8201;99% required hospital admission. With a 30-day mortality rate of 12.1%, this was significantly higher than the in-hospital mortality rate of 2.1%, although our in-hospital mortality rate was significantly higher at 13.5%. One potential explanation for this discrepancy is that in our study, over 60% of patients were transferred to an ICU or IMC, a figure that is significantly lower than that observed in the Ball et al. study, in which less than 10% of patients were transferred to such a facility [<xref ref-type="bibr" rid="CR43">43</xref>]. A recent meta-analysis investigating the effect of cardioselective &#946;-blockers on mortality in septic shock showed an improved 28-day mortality rate. However, esmolol showed this positive effect that could not be demonstrated for Landiolol. It was also shown that there was an improved peripheral perfusion and an improvement in the stroke volume of the heart [<xref ref-type="bibr" rid="CR44">44</xref>]. In particular, at the prehospital stage, there could be concerns that there may be clinical deterioration in terms of reduced organ perfusion or worsening unknown left ventricular ejection fraction during tachycardia and thus again leads to a hypoperfusion state. To find the correct indication of &#223;-blockers could help to improve this pathophysiological situation.</p></sec><sec id="Sec456"><title>Other antiarrhythmic medication</title><p id="Par45">In our study, in addition to Landiolol, antiarrhythmic drugs such as Amiodarone or Metoprolol were also administered. We were unable to show any significant differences in the hemodynamic and antiarrhythmic effects between the groups, but an impact on the efficacy of Landiolol or the examined parameters cannot be ruled out entirely.</p></sec><sec id="Sec1678"><title>Duration of hospitalization</title><p id="Par46">However, if we look at the early treatment of prehospital dysrhythmias in relation to the length of hospitalisation with significantly less selective medications, as in Fornage et al. (mostly diltiazem) of 4.2 vs. 5.0 days in non-treat patients. In this context, the implementation of an early treatment strategy may potentially result in indirect cost savings by reducing the length of hospitalization for patients. Even if no significant reduction in the length of stay in the emergency department could be shown for untreated patients compared to those treated prehospitally (5.6 vs. 5.1) [<xref ref-type="bibr" rid="CR41">41</xref>]. The findings of our study indicate a notable reduction in the length of hospitalisation, with an average duration of 2 days. Notably, over 50% of patients admitted to hospital were discharged to their place of residence as early as day 2.</p></sec><sec id="Sec13"><title>Limitations</title><p id="Par47">Our study has several major limitations: (1) The first and obviously the major limitation is that our study is a retrospective analysis of a relatively small cohort of 111 patients, without any randomization or blinding. (2) The study population comprised solely of patients treated with Landiolol, and no comparison group was included, either with a standard-of-care group or a group treated with a different drug. (3) Due to the retrospective nature of the study, not all of the data collected was available in its entirety and the quality of the data was heavily dependent on the documentation of the emergency physicians and paramedics, the documentation by the local staff upon hospital admission, and the precise recording and storage of the vital parameters in the available defibrillators and monitors. (4) The lack of standardization and heterogeneity of the data, resulting from the disparate documentation of vital parameters during the course of the operations, meant that only the initial value and the final measured value prior to the patient&#8217;s arrival at the hospital were available for analysis. Consequently, the full course of the patient&#8217;s condition could not be presented in a comprehensive manner throughout the entirety of their care by the ambulance service. (5) The elevated costs of Landiolol in comparison to alternative antiarrhythmic agents must be substantiated, and future investigations will be required to ascertain whether, as is the case in intensive care medicine, its utilization can result in cost savings. This remains uncertain at present. (6) Furthermore, it would be interesting to find out whether chronic oral &#223;-blocker intake has an impact on the effect of Landiolol in the described setting. (7) Additionally, the effect of Landiolol in patients with limited left ventricular function and signs of heart failure, whether acute or chronic, should be examined.</p></sec></sec><sec id="Sec14"><title>Conclusion</title><p id="Par48">This first description of prehospital push-dose Landiolol suggests that its use may offer a promising therapeutic option in EMS patients with tachydysrhythmia, with over 50% of assessed patients experiencing a clinical improvement. General feasibility of administering Landiolol in the prehospital environment was demonstrated, and the agent showed effectiveness in rapidly reducing heart rate or terminating arrhythmias.</p><p id="Par49">Clinically relevant drops in blood pressure were observed in a very small subset of patients, highlighting the need for careful patient selection and monitoring. Additionally, potential rhythm control effects must be further investigated because of the underlying potential need of anticoagulation. Further prospective studies will be essential to define the optimal use of prehospital Landiolol and compare it to other antiarrhythmic agents.</p></sec><sec id="Sec15" sec-type="supplementary-material"><title>Electronic supplementary material</title><p>Below is the link to the electronic supplementary material.</p><p>
<supplementary-material content-type="local-data" id="MOESM1" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="13049_2025_1438_MOESM1_ESM.docx" position="float" orientation="portrait"><caption><p>Supplementary Material 1</p></caption></media></supplementary-material>
</p><p>
<supplementary-material content-type="local-data" id="MOESM2" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="13049_2025_1438_MOESM2_ESM.docx" position="float" orientation="portrait"><caption><p>Supplementary Material 2</p></caption></media></supplementary-material>
</p></sec></body><back><fn-group><fn><p><bold>Publisher&#8217;s note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p>Felix Eibensteiner and Mario Krammel have contributed equally to this work.</p></fn></fn-group><ack><title>Acknowledgements</title><p>We would like to extend our gratitude to all those who contributed to the acquisition of data for this study, and to all paramedics and emergency physicians involved in the treatment of the respective patients.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>All authors were involved in the acquisition of data and the design of the study. FE, MK, and SS drafted the manuscript and conducted the data analyses. All authors provided critical revisions to the manuscript and contributed valuable input. SS, HD, and PS supervised the study process. All authors have read and agreed to the published version of the manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>None.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>Upon reasonable request, the corresponding author will furnish data in accordance with national legislation.</p></notes><notes><title>Declarations</title><notes id="FPar8"><title>Ethics approval and consent to participate</title><p id="Par50">for this study was given by the Ethical Committee of the Medical University of Vienna, Austria (No. 1442/2021). The study protocol complies with the Declaration of Helsinki.</p></notes><notes id="FPar9"><title>Consent of publication</title><p id="Par51">Not applicable.</p></notes><notes id="FPar1" notes-type="COI-statement"><title>Competing interests</title><p id="Par52">Sebastian Schnaubelt has in the past received speakers&#8217; fees and research grants from AOP Health. However, AOP Health was not involved in the planning, analysis, or presentation of this study. He also declares to be member of the Advanced Life Support Science and Education Committee of the European Resuscitation Council. The rest of the authors declare to not have any (potential) conflicts of interest.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roth</surname><given-names>GA</given-names></name><name name-style="western"><surname>Mensah</surname><given-names>GA</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>CO</given-names></name><name name-style="western"><surname>Addolorato</surname><given-names>G</given-names></name><name name-style="western"><surname>Ammirati</surname><given-names>E</given-names></name><name name-style="western"><surname>Baddour</surname><given-names>LM</given-names></name><name name-style="western"><surname>Barengo</surname><given-names>NC</given-names></name><name name-style="western"><surname>Beaton</surname><given-names>AZ</given-names></name><name name-style="western"><surname>Benjamin</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Benziger</surname><given-names>CP</given-names></name><etal/></person-group><article-title>Global burden of cardiovascular diseases and risk factors, 1990&#8211;2019: update from the GBD 2019 study</article-title><source>J Am Coll Cardiol</source><year>2020</year><volume>76</volume><issue>25</issue><fpage>2982</fpage><lpage>3021</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2020.11.010</pub-id><pub-id pub-id-type="pmid">33309175</pub-id><pub-id pub-id-type="pmcid">PMC7755038</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, Barengo NC, Beaton AZ, Benjamin EJ, Benziger CP, et al. Global burden of cardiovascular diseases and risk factors, 1990&#8211;2019: update from the GBD 2019 study. J Am Coll Cardiol. 2020;76(25):2982&#8211;3021.<pub-id pub-id-type="pmid">33309175</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jacc.2020.11.010</pub-id><pub-id pub-id-type="pmcid">PMC7755038</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kotadia</surname><given-names>ID</given-names></name><name name-style="western"><surname>Williams</surname><given-names>SE</given-names></name><name name-style="western"><surname>O&#8217;Neill</surname><given-names>M</given-names></name></person-group><article-title>Supraventricular tachycardia: an overview of diagnosis and management</article-title><source>Clin Med (Lond)</source><year>2020</year><volume>20</volume><issue>1</issue><fpage>43</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.7861/clinmed.cme.20.1.3</pub-id><pub-id pub-id-type="pmid">31941731</pub-id><pub-id pub-id-type="pmcid">PMC6964177</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Kotadia ID, Williams SE, O&#8217;Neill M. Supraventricular tachycardia: an overview of diagnosis and management. Clin Med (Lond). 2020;20(1):43&#8211;7.<pub-id pub-id-type="pmid">31941731</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7861/clinmed.cme.20.1.3</pub-id><pub-id pub-id-type="pmcid">PMC6964177</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zeppenfeld</surname><given-names>K</given-names></name><name name-style="western"><surname>Tfelt-Hansen</surname><given-names>J</given-names></name><name name-style="western"><surname>de Riva</surname><given-names>M</given-names></name><name name-style="western"><surname>Winkel</surname><given-names>BG</given-names></name><name name-style="western"><surname>Behr</surname><given-names>ER</given-names></name><name name-style="western"><surname>Blom</surname><given-names>NA</given-names></name><name name-style="western"><surname>Charron</surname><given-names>P</given-names></name><name name-style="western"><surname>Corrado</surname><given-names>D</given-names></name><name name-style="western"><surname>Dagres</surname><given-names>N</given-names></name><name name-style="western"><surname>de Chillou</surname><given-names>C</given-names></name><etal/></person-group><article-title>2022 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: developed by the task force for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death of the European society of cardiology (ESC) endorsed by the association for European paediatric and congenital cardiology (AEPC)</article-title><source>Eur Heart J</source><year>2022</year><volume>43</volume><issue>40</issue><fpage>3997</fpage><lpage>4126</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehac262</pub-id><pub-id pub-id-type="pmid">36017572</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Zeppenfeld K, Tfelt-Hansen J, de Riva M, Winkel BG, Behr ER, Blom NA, Charron P, Corrado D, Dagres N, de Chillou C, et al. 2022 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: developed by the task force for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death of the European society of cardiology (ESC) endorsed by the association for European paediatric and congenital cardiology (AEPC). Eur Heart J. 2022;43(40):3997&#8211;4126.<pub-id pub-id-type="pmid">36017572</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/eurheartj/ehac262</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><mixed-citation publication-type="other">Sirichand S, Killu AM, Padmanabhan D, Hodge DO, Chamberlain AM, Brady PA, Kapa S, Noseworthy PA, Packer DL, Munger TM et al. Incidence of idiopathic ventricular arrhythmias: A Population-Based study. Circ Arrhythm Electrophysiol 2017;10(2).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/CIRCEP.116.004662</pub-id><pub-id pub-id-type="pmcid">PMC5319731</pub-id><pub-id pub-id-type="pmid">28183845</pub-id></mixed-citation></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Piccini</surname><given-names>JP</given-names></name><name name-style="western"><surname>Schulte</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Pieper</surname><given-names>KS</given-names></name><name name-style="western"><surname>Mehta</surname><given-names>RH</given-names></name><name name-style="western"><surname>White</surname><given-names>HD</given-names></name><name name-style="western"><surname>Van de Werf</surname><given-names>F</given-names></name><name name-style="western"><surname>Ardissino</surname><given-names>D</given-names></name><name name-style="western"><surname>Califf</surname><given-names>RM</given-names></name><name name-style="western"><surname>Granger</surname><given-names>CB</given-names></name><name name-style="western"><surname>Ohman</surname><given-names>EM</given-names></name><etal/></person-group><article-title>Antiarrhythmic drug therapy for sustained ventricular arrhythmias complicating acute myocardial infarction*</article-title><source>Crit Care Med</source><year>2011</year><volume>39</volume><issue>1</issue><fpage>78</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1097/CCM.0b013e3181fd6ad7</pub-id><pub-id pub-id-type="pmid">20959785</pub-id><pub-id pub-id-type="pmcid">PMC3010352</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Piccini JP, Schulte PJ, Pieper KS, Mehta RH, White HD, Van de Werf F, Ardissino D, Califf RM, Granger CB, Ohman EM, et al. Antiarrhythmic drug therapy for sustained ventricular arrhythmias complicating acute myocardial infarction*. Crit Care Med. 2011;39(1):78&#8211;83.<pub-id pub-id-type="pmid">20959785</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/CCM.0b013e3181fd6ad7</pub-id><pub-id pub-id-type="pmcid">PMC3010352</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Soar</surname><given-names>J</given-names></name><name name-style="western"><surname>B&#246;ttiger</surname><given-names>BW</given-names></name><name name-style="western"><surname>Carli</surname><given-names>P</given-names></name><name name-style="western"><surname>Couper</surname><given-names>K</given-names></name><name name-style="western"><surname>Deakin</surname><given-names>CD</given-names></name><name name-style="western"><surname>Dj&#228;rv</surname><given-names>T</given-names></name><name name-style="western"><surname>Lott</surname><given-names>C</given-names></name><name name-style="western"><surname>Olasveengen</surname><given-names>T</given-names></name><name name-style="western"><surname>Paal</surname><given-names>P</given-names></name><name name-style="western"><surname>Pellis</surname><given-names>T</given-names></name><etal/></person-group><article-title>European resuscitation Council guidelines 2021: adult advanced life support</article-title><source>Resuscitation</source><year>2021</year><volume>161</volume><fpage>115</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1016/j.resuscitation.2021.02.010</pub-id><pub-id pub-id-type="pmid">33773825</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Soar J, B&#246;ttiger BW, Carli P, Couper K, Deakin CD, Dj&#228;rv T, Lott C, Olasveengen T, Paal P, Pellis T, et al. European resuscitation Council guidelines 2021: adult advanced life support. Resuscitation. 2021;161:115&#8211;51.<pub-id pub-id-type="pmid">33773825</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.resuscitation.2021.02.010</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van Gelder</surname><given-names>IC</given-names></name><name name-style="western"><surname>Rienstra</surname><given-names>M</given-names></name><name name-style="western"><surname>Bunting</surname><given-names>KV</given-names></name><name name-style="western"><surname>Casado-Arroyo</surname><given-names>R</given-names></name><name name-style="western"><surname>Caso</surname><given-names>V</given-names></name><name name-style="western"><surname>Crijns</surname><given-names>HJGM</given-names></name><name name-style="western"><surname>De Potter</surname><given-names>TJR</given-names></name><name name-style="western"><surname>Dwight</surname><given-names>J</given-names></name><name name-style="western"><surname>Guasti</surname><given-names>L</given-names></name><name name-style="western"><surname>Hanke</surname><given-names>T</given-names></name><etal/></person-group><article-title>: 2024 ESC guidelines for the management of atrial fibrillation developed in collaboration with the European association for Cardio-Thoracic surgery (EACTS): developed by the task force for the management of atrial fibrillation of the European society of cardiology (ESC), with the special contribution of the European heart rhythm association (EHRA) of the ESC. Endorsed by the European stroke organisation (ESO)</article-title><source>Eur Heart J</source><year>2024</year><volume>45</volume><issue>36</issue><fpage>3314</fpage><lpage>414</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehae176</pub-id><pub-id pub-id-type="pmid">39210723</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Van Gelder IC, Rienstra M, Bunting KV, Casado-Arroyo R, Caso V, Crijns HJGM, De Potter TJR, Dwight J, Guasti L, Hanke T, et al.: 2024 ESC guidelines for the management of atrial fibrillation developed in collaboration with the European association for Cardio-Thoracic surgery (EACTS): developed by the task force for the management of atrial fibrillation of the European society of cardiology (ESC), with the special contribution of the European heart rhythm association (EHRA) of the ESC. Endorsed by the European stroke organisation (ESO). Eur Heart J. 2024;45(36):3314&#8211;414.<pub-id pub-id-type="pmid">39210723</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/eurheartj/ehae176</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bedford</surname><given-names>JP</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>A</given-names></name><name name-style="western"><surname>Redfern</surname><given-names>O</given-names></name><name name-style="western"><surname>Gerry</surname><given-names>S</given-names></name><name name-style="western"><surname>Doidge</surname><given-names>J</given-names></name><name name-style="western"><surname>Harrison</surname><given-names>D</given-names></name><name name-style="western"><surname>Rajappan</surname><given-names>K</given-names></name><name name-style="western"><surname>Rowan</surname><given-names>K</given-names></name><name name-style="western"><surname>Young</surname><given-names>JD</given-names></name><name name-style="western"><surname>Mouncey</surname><given-names>P</given-names></name><etal/></person-group><article-title>Comparative effectiveness of common treatments for new-onset atrial fibrillation within the ICU: accounting for physiological status</article-title><source>J Crit Care</source><year>2022</year><volume>67</volume><fpage>149</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1016/j.jcrc.2021.11.005</pub-id><pub-id pub-id-type="pmid">34798373</pub-id><pub-id pub-id-type="pmcid">PMC8687206</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Bedford JP, Johnson A, Redfern O, Gerry S, Doidge J, Harrison D, Rajappan K, Rowan K, Young JD, Mouncey P, et al. Comparative effectiveness of common treatments for new-onset atrial fibrillation within the ICU: accounting for physiological status. J Crit Care. 2022;67:149&#8211;56.<pub-id pub-id-type="pmid">34798373</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jcrc.2021.11.005</pub-id><pub-id pub-id-type="pmcid">PMC8687206</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Walkey</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Evans</surname><given-names>SR</given-names></name><name name-style="western"><surname>Winter</surname><given-names>MR</given-names></name><name name-style="western"><surname>Benjamin</surname><given-names>EJ</given-names></name></person-group><article-title>Practice patterns and outcomes of treatments for atrial fibrillation during sepsis: A Propensity-Matched cohort study</article-title><source>Chest</source><year>2016</year><volume>149</volume><issue>1</issue><fpage>74</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1378/chest.15-0959</pub-id><pub-id pub-id-type="pmid">26270396</pub-id><pub-id pub-id-type="pmcid">PMC4944768</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Walkey AJ, Evans SR, Winter MR, Benjamin EJ. Practice patterns and outcomes of treatments for atrial fibrillation during sepsis: A Propensity-Matched cohort study. Chest. 2016;149(1):74&#8211;83.<pub-id pub-id-type="pmid">26270396</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1378/chest.15-0959</pub-id><pub-id pub-id-type="pmcid">PMC4944768</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Balik</surname><given-names>M</given-names></name><name name-style="western"><surname>Kolnikova</surname><given-names>I</given-names></name><name name-style="western"><surname>Maly</surname><given-names>M</given-names></name><name name-style="western"><surname>Waldauf</surname><given-names>P</given-names></name><name name-style="western"><surname>Tavazzi</surname><given-names>G</given-names></name><name name-style="western"><surname>Kristof</surname><given-names>J</given-names></name></person-group><article-title>Propafenone for supraventricular arrhythmias in septic shock&#8212;Comparison to Amiodarone and Metoprolol</article-title><source>J Crit Care</source><year>2017</year><volume>41</volume><fpage>16</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1016/j.jcrc.2017.04.027</pub-id><pub-id pub-id-type="pmid">28463737</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Balik M, Kolnikova I, Maly M, Waldauf P, Tavazzi G, Kristof J. Propafenone for supraventricular arrhythmias in septic shock&#8212;Comparison to Amiodarone and Metoprolol. J Crit Care. 2017;41:16&#8211;23.<pub-id pub-id-type="pmid">28463737</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jcrc.2017.04.027</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fatima</surname><given-names>N</given-names></name><name name-style="western"><surname>Mandava</surname><given-names>K</given-names></name><name name-style="western"><surname>Khatoon</surname><given-names>F</given-names></name><name name-style="western"><surname>Badar</surname><given-names>J</given-names></name><name name-style="western"><surname>Begum</surname><given-names>SF</given-names></name><name name-style="western"><surname>Narasimhan</surname><given-names>C</given-names></name><name name-style="western"><surname>Daljeet</surname><given-names>K</given-names></name><name name-style="western"><surname>Mohammed</surname><given-names>W</given-names></name></person-group><article-title>CLInical profile and side effects of chronic use of oral Amiodarone in cardiology outpatients department (CLIPSE-A Study)- A prospective observational study</article-title><source>Annals Med Surg</source><year>2022</year><volume>80</volume><fpage>104167</fpage><pub-id pub-id-type="doi">10.1016/j.amsu.2022.104167</pub-id><pub-id pub-id-type="pmcid">PMC9422214</pub-id><pub-id pub-id-type="pmid">36045807</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Fatima N, Mandava K, Khatoon F, Badar J, Begum SF, Narasimhan C, Daljeet K, Mohammed W. CLInical profile and side effects of chronic use of oral Amiodarone in cardiology outpatients department (CLIPSE-A Study)- A prospective observational study. Annals Med Surg. 2022;80:104167.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.amsu.2022.104167</pub-id><pub-id pub-id-type="pmcid">PMC9422214</pub-id><pub-id pub-id-type="pmid">36045807</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Drikite</surname><given-names>L</given-names></name><name name-style="western"><surname>Bedford</surname><given-names>JP</given-names></name><name name-style="western"><surname>O&#8217;Bryan</surname><given-names>L</given-names></name><name name-style="western"><surname>Petrinic</surname><given-names>T</given-names></name><name name-style="western"><surname>Rajappan</surname><given-names>K</given-names></name><name name-style="western"><surname>Doidge</surname><given-names>J</given-names></name><name name-style="western"><surname>Harrison</surname><given-names>DA</given-names></name><name name-style="western"><surname>Rowan</surname><given-names>KM</given-names></name><name name-style="western"><surname>Mouncey</surname><given-names>PR</given-names></name><name name-style="western"><surname>Young</surname><given-names>D</given-names></name><etal/></person-group><article-title>Treatment strategies for new onset atrial fibrillation in patients treated on an intensive care unit: a systematic scoping review</article-title><source>Crit Care</source><year>2021</year><volume>25</volume><issue>1</issue><fpage>257</fpage><pub-id pub-id-type="doi">10.1186/s13054-021-03684-5</pub-id><pub-id pub-id-type="pmid">34289899</pub-id><pub-id pub-id-type="pmcid">PMC8296751</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Drikite L, Bedford JP, O&#8217;Bryan L, Petrinic T, Rajappan K, Doidge J, Harrison DA, Rowan KM, Mouncey PR, Young D, et al. Treatment strategies for new onset atrial fibrillation in patients treated on an intensive care unit: a systematic scoping review. Crit Care. 2021;25(1):257.<pub-id pub-id-type="pmid">34289899</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13054-021-03684-5</pub-id><pub-id pub-id-type="pmcid">PMC8296751</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Medi&#263;</surname><given-names>F</given-names></name><name name-style="western"><surname>Bakula</surname><given-names>M</given-names></name><name name-style="western"><surname>Alfirevi&#263;</surname><given-names>M</given-names></name><name name-style="western"><surname>Bakula</surname><given-names>M</given-names></name><name name-style="western"><surname>Muci&#263;</surname><given-names>K</given-names></name><name name-style="western"><surname>Mari&#263;</surname><given-names>N</given-names></name></person-group><article-title>AMIODARONE AND THYROID DYSFUNCTION</article-title><source>Acta Clin Croat</source><year>2022</year><volume>61</volume><issue>2</issue><fpage>327</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">36818930</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.20471/acc.2022.61.02.20</pub-id><pub-id pub-id-type="pmcid">PMC9934045</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Medi&#263; F, Bakula M, Alfirevi&#263; M, Bakula M, Muci&#263; K, Mari&#263; N. AMIODARONE AND THYROID DYSFUNCTION. Acta Clin Croat. 2022;61(2):327&#8211;41.<pub-id pub-id-type="pmid">36818930</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.20471/acc.2022.61.02.20</pub-id><pub-id pub-id-type="pmcid">PMC9934045</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ruzieh</surname><given-names>M</given-names></name><name name-style="western"><surname>Moroi</surname><given-names>MK</given-names></name><name name-style="western"><surname>Aboujamous</surname><given-names>NM</given-names></name><name name-style="western"><surname>Ghahramani</surname><given-names>M</given-names></name><name name-style="western"><surname>Naccarelli</surname><given-names>GV</given-names></name><name name-style="western"><surname>Mandrola</surname><given-names>J</given-names></name><name name-style="western"><surname>Foy</surname><given-names>AJ</given-names></name></person-group><article-title>Meta-Analysis comparing the relative risk of adverse events for Amiodarone versus placebo</article-title><source>Am J Cardiol</source><year>2019</year><volume>124</volume><issue>12</issue><fpage>1889</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1016/j.amjcard.2019.09.008</pub-id><pub-id pub-id-type="pmid">31653351</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Ruzieh M, Moroi MK, Aboujamous NM, Ghahramani M, Naccarelli GV, Mandrola J, Foy AJ. Meta-Analysis comparing the relative risk of adverse events for Amiodarone versus placebo. Am J Cardiol. 2019;124(12):1889&#8211;93.<pub-id pub-id-type="pmid">31653351</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.amjcard.2019.09.008</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brugada</surname><given-names>J</given-names></name><name name-style="western"><surname>Katritsis</surname><given-names>DG</given-names></name><name name-style="western"><surname>Arbelo</surname><given-names>E</given-names></name><name name-style="western"><surname>Arribas</surname><given-names>F</given-names></name><name name-style="western"><surname>Bax</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Blomstr&#246;m-Lundqvist</surname><given-names>C</given-names></name><name name-style="western"><surname>Calkins</surname><given-names>H</given-names></name><name name-style="western"><surname>Corrado</surname><given-names>D</given-names></name><name name-style="western"><surname>Deftereos</surname><given-names>SG</given-names></name><name name-style="western"><surname>Diller</surname><given-names>G-P</given-names></name><etal/></person-group><article-title>2019 ESC guidelines for the management of patients with supraventricular tachycardiathe task force for the management of patients with supraventricular tachycardia of the European society of cardiology (ESC): developed in collaboration with the association for European paediatric and congenital cardiology (AEPC)</article-title><source>Eur Heart J</source><year>2019</year><volume>41</volume><issue>5</issue><fpage>655</fpage><lpage>720</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehz467</pub-id><pub-id pub-id-type="pmid">31504425</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Brugada J, Katritsis DG, Arbelo E, Arribas F, Bax JJ, Blomstr&#246;m-Lundqvist C, Calkins H, Corrado D, Deftereos SG, Diller G-P, et al. 2019 ESC guidelines for the management of patients with supraventricular tachycardiathe task force for the management of patients with supraventricular tachycardia of the European society of cardiology (ESC): developed in collaboration with the association for European paediatric and congenital cardiology (AEPC). Eur Heart J. 2019;41(5):655&#8211;720.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/eurheartj/ehz467</pub-id><pub-id pub-id-type="pmid">31504425</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gorre</surname><given-names>F</given-names></name><name name-style="western"><surname>Vandekerckhove</surname><given-names>H</given-names></name></person-group><article-title>Beta-blockers: focus on mechanism of action. Which beta-blocker, when and why?</article-title><source>Acta Cardiol</source><year>2010</year><volume>65</volume><issue>5</issue><fpage>565</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1080/AC.65.5.2056244</pub-id><pub-id pub-id-type="pmid">21125979</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Gorre F, Vandekerckhove H. Beta-blockers: focus on mechanism of action. Which beta-blocker, when and why? Acta Cardiol. 2010;65(5):565&#8211;70.<pub-id pub-id-type="pmid">21125979</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/ac.65.5.2056244</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><mixed-citation publication-type="other">Wong GWK, Boyda HN, Wright JM. Blood pressure Lowering efficacy of beta-1 selective beta blockers for primary hypertension. Cochrane Database Syst Reviews 2016;(3).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/14651858.CD007451.pub2</pub-id><pub-id pub-id-type="pmcid">PMC6486283</pub-id><pub-id pub-id-type="pmid">26961574</pub-id></mixed-citation></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gorczynski</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Shaffer</surname><given-names>JE</given-names></name><name name-style="western"><surname>Lee</surname><given-names>RJ</given-names></name></person-group><article-title>Pharmacology of ASL-8052, a novel &#946;-Adrenergic receptor antagonist with an ultrashort duration of action</article-title><source>J Cardiovasc Pharmacol</source><year>1983</year><volume>5</volume><issue>4</issue><fpage>668</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.1097/00005344-198307000-00023</pub-id><pub-id pub-id-type="pmid">6193366</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Gorczynski RJ, Shaffer JE, Lee RJ. Pharmacology of ASL-8052, a novel &#946;-Adrenergic receptor antagonist with an ultrashort duration of action. J Cardiovasc Pharmacol. 1983;5(4):668&#8211;77.<pub-id pub-id-type="pmid">6193366</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00005344-198307000-00023</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wiest</surname><given-names>D</given-names></name></person-group><article-title>Esmolol. A review of its therapeutic efficacy and Pharmacokinetic characteristics</article-title><source>Clin Pharmacokinet</source><year>1995</year><volume>28</volume><issue>3</issue><fpage>190</fpage><lpage>202</lpage><pub-id pub-id-type="doi">10.2165/00003088-199528030-00002</pub-id><pub-id pub-id-type="pmid">7758250</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Wiest D. Esmolol. A review of its therapeutic efficacy and Pharmacokinetic characteristics. Clin Pharmacokinet. 1995;28(3):190&#8211;202.<pub-id pub-id-type="pmid">7758250</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2165/00003088-199528030-00002</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iguchi</surname><given-names>S</given-names></name><name name-style="western"><surname>Iwamura</surname><given-names>H</given-names></name><name name-style="western"><surname>Nishizaki</surname><given-names>M</given-names></name><name name-style="western"><surname>Hayashi</surname><given-names>A</given-names></name><name name-style="western"><surname>Senokuchi</surname><given-names>K</given-names></name><name name-style="western"><surname>Kobayashi</surname><given-names>K</given-names></name><name name-style="western"><surname>Sakaki</surname><given-names>K</given-names></name><name name-style="western"><surname>Hachiya</surname><given-names>K</given-names></name><name name-style="western"><surname>Ichioka</surname><given-names>Y</given-names></name><name name-style="western"><surname>Kawamura</surname><given-names>M</given-names></name></person-group><article-title>Development of a highly cardioselective ultra short-acting beta-blocker, ONO-1101</article-title><source>Chem Pharm Bull (Tokyo)</source><year>1992</year><volume>40</volume><issue>6</issue><fpage>1462</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1248/cpb.40.1462</pub-id><pub-id pub-id-type="pmid">1356643</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Iguchi S, Iwamura H, Nishizaki M, Hayashi A, Senokuchi K, Kobayashi K, Sakaki K, Hachiya K, Ichioka Y, Kawamura M. Development of a highly cardioselective ultra short-acting beta-blocker, ONO-1101. Chem Pharm Bull (Tokyo). 1992;40(6):1462&#8211;9.<pub-id pub-id-type="pmid">1356643</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1248/cpb.40.1462</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Atarashi</surname><given-names>H</given-names></name><name name-style="western"><surname>Kuruma</surname><given-names>A</given-names></name><name name-style="western"><surname>Yashima</surname><given-names>M</given-names></name><name name-style="western"><surname>Saitoh</surname><given-names>H</given-names></name><name name-style="western"><surname>Ino</surname><given-names>T</given-names></name><name name-style="western"><surname>Endoh</surname><given-names>Y</given-names></name><name name-style="western"><surname>Hayakawa</surname><given-names>H</given-names></name></person-group><article-title>Pharmacokinetics of Landiolol hydrochloride, a new ultra-short-acting beta-blocker, in patients with cardiac arrhythmias</article-title><source>Clin Pharmacol Ther</source><year>2000</year><volume>68</volume><issue>2</issue><fpage>143</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1067/mcp.2000.108733</pub-id><pub-id pub-id-type="pmid">10976545</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Atarashi H, Kuruma A, Yashima M, Saitoh H, Ino T, Endoh Y, Hayakawa H. Pharmacokinetics of Landiolol hydrochloride, a new ultra-short-acting beta-blocker, in patients with cardiac arrhythmias. Clin Pharmacol Ther. 2000;68(2):143&#8211;50.<pub-id pub-id-type="pmid">10976545</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1067/mcp.2000.108733</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krumpl</surname><given-names>G</given-names></name><name name-style="western"><surname>Ulc</surname><given-names>I</given-names></name><name name-style="western"><surname>Trebs</surname><given-names>M</given-names></name><name name-style="western"><surname>Kadlecov&#225;</surname><given-names>P</given-names></name><name name-style="western"><surname>Hodisch</surname><given-names>J</given-names></name></person-group><article-title>Pharmacokinetics and pharmacodynamics of two different Landiolol formulations in a healthy Caucasian group</article-title><source>Eur J Pharm Sci</source><year>2016</year><volume>92</volume><fpage>64</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1016/j.ejps.2016.06.022</pub-id><pub-id pub-id-type="pmid">27373605</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Krumpl G, Ulc I, Trebs M, Kadlecov&#225; P, Hodisch J. Pharmacokinetics and pharmacodynamics of two different Landiolol formulations in a healthy Caucasian group. Eur J Pharm Sci. 2016;92:64&#8211;73.<pub-id pub-id-type="pmid">27373605</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejps.2016.06.022</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iwahashi</surname><given-names>N</given-names></name><name name-style="western"><surname>Takahashi</surname><given-names>H</given-names></name><name name-style="western"><surname>Abe</surname><given-names>T</given-names></name><name name-style="western"><surname>Okada</surname><given-names>K</given-names></name><name name-style="western"><surname>Akiyama</surname><given-names>E</given-names></name><name name-style="western"><surname>Matsuzawa</surname><given-names>Y</given-names></name><name name-style="western"><surname>Konishi</surname><given-names>M</given-names></name><name name-style="western"><surname>Maejima</surname><given-names>N</given-names></name><name name-style="western"><surname>Hibi</surname><given-names>K</given-names></name><name name-style="western"><surname>Kosuge</surname><given-names>M</given-names></name><etal/></person-group><article-title>Urgent control of rapid atrial fibrillation by Landiolol in patients with acute decompensated heart failure with severely reduced ejection fraction</article-title><source>Circ Rep</source><year>2019</year><volume>1</volume><issue>10</issue><fpage>422</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1253/circrep.CR-19-0076</pub-id><pub-id pub-id-type="pmid">33693079</pub-id><pub-id pub-id-type="pmcid">PMC7897576</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Iwahashi N, Takahashi H, Abe T, Okada K, Akiyama E, Matsuzawa Y, Konishi M, Maejima N, Hibi K, Kosuge M, et al. Urgent control of rapid atrial fibrillation by Landiolol in patients with acute decompensated heart failure with severely reduced ejection fraction. Circ Rep. 2019;1(10):422&#8211;30.<pub-id pub-id-type="pmid">33693079</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1253/circrep.CR-19-0076</pub-id><pub-id pub-id-type="pmcid">PMC7897576</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><mixed-citation publication-type="other">Schnaubelt S, Eibensteiner F, Oppenauer J, Tihanyi D, Neymayer M, Brock R, Kornfehl A, Veigl C, Al Jalali V, Anders S et al. Hemodynamic and rhythmologic effects of Push-Dose Landiolol in critical Care-A retrospective Cross-Sectional study. Pharmaceuticals (Basel) 2023;16(2).<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ph16020134</pub-id><pub-id pub-id-type="pmcid">PMC9967759</pub-id><pub-id pub-id-type="pmid">37259286</pub-id></mixed-citation></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Johnston</surname><given-names>BW</given-names></name><name name-style="western"><surname>Chean</surname><given-names>CS</given-names></name><name name-style="western"><surname>Duarte</surname><given-names>R</given-names></name><name name-style="western"><surname>Hill</surname><given-names>R</given-names></name><name name-style="western"><surname>Blackwood</surname><given-names>B</given-names></name><name name-style="western"><surname>McAuley</surname><given-names>DF</given-names></name><name name-style="western"><surname>Welters</surname><given-names>ID</given-names></name></person-group><article-title>Management of new onset atrial fibrillation in critically unwell adult patients: a systematic review and narrative synthesis</article-title><source>Br J Anaesth</source><year>2022</year><volume>128</volume><issue>5</issue><fpage>759</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1016/j.bja.2021.11.016</pub-id><pub-id pub-id-type="pmid">34916053</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Johnston BW, Chean CS, Duarte R, Hill R, Blackwood B, McAuley DF, Welters ID. Management of new onset atrial fibrillation in critically unwell adult patients: a systematic review and narrative synthesis. Br J Anaesth. 2022;128(5):759&#8211;71.<pub-id pub-id-type="pmid">34916053</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bja.2021.11.016</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van Gelder</surname><given-names>IC</given-names></name><name name-style="western"><surname>Hemels</surname><given-names>MEW</given-names></name></person-group><article-title>The progressive nature of atrial fibrillation: a rationale for early restoration and maintenance of sinus rhythm</article-title><source>EP Europace</source><year>2006</year><volume>8</volume><issue>11</issue><fpage>943</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1093/europace/eul107</pub-id><pub-id pub-id-type="pmid">16973685</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Van Gelder IC, Hemels MEW. The progressive nature of atrial fibrillation: a rationale for early restoration and maintenance of sinus rhythm. EP Europace. 2006;8(11):943&#8211;9.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/europace/eul107</pub-id><pub-id pub-id-type="pmid">16973685</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gupta</surname><given-names>D</given-names></name><name name-style="western"><surname>Rienstra</surname><given-names>M</given-names></name><name name-style="western"><surname>van Gelder</surname><given-names>IC</given-names></name><name name-style="western"><surname>Fauchier</surname><given-names>L</given-names></name></person-group><article-title>Atrial fibrillation: better symptom control with rate and rhythm management</article-title><source>Lancet Reg Health - Europe</source><year>2024</year><volume>37</volume><fpage>100801</fpage><pub-id pub-id-type="doi">10.1016/j.lanepe.2023.100801</pub-id><pub-id pub-id-type="pmid">38362560</pub-id><pub-id pub-id-type="pmcid">PMC10866934</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Gupta D, Rienstra M, van Gelder IC, Fauchier L. Atrial fibrillation: better symptom control with rate and rhythm management. Lancet Reg Health - Europe. 2024;37:100801.<pub-id pub-id-type="pmid">38362560</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.lanepe.2023.100801</pub-id><pub-id pub-id-type="pmcid">PMC10866934</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Levy</surname><given-names>B</given-names></name><name name-style="western"><surname>Slama</surname><given-names>M</given-names></name><name name-style="western"><surname>Lakbar</surname><given-names>I</given-names></name><name name-style="western"><surname>Maizel</surname><given-names>J</given-names></name><name name-style="western"><surname>Kato</surname><given-names>H</given-names></name><name name-style="western"><surname>Leone</surname><given-names>M</given-names></name><name name-style="western"><surname>Okada</surname><given-names>M</given-names></name></person-group><article-title>Landiolol for treatment of New-Onset atrial fibrillation in critical care: A systematic review</article-title><source>J Clin Med</source><year>2024</year><volume>13</volume><issue>10</issue><fpage>2951</fpage><pub-id pub-id-type="doi">10.3390/jcm13102951</pub-id><pub-id pub-id-type="pmid">38792492</pub-id><pub-id pub-id-type="pmcid">PMC11122541</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Levy B, Slama M, Lakbar I, Maizel J, Kato H, Leone M, Okada M. Landiolol for treatment of New-Onset atrial fibrillation in critical care: A systematic review. J Clin Med. 2024;13(10):2951.<pub-id pub-id-type="pmid">38792492</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/jcm13102951</pub-id><pub-id pub-id-type="pmcid">PMC11122541</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krumpl</surname><given-names>G</given-names></name><name name-style="western"><surname>Ulc</surname><given-names>I</given-names></name><name name-style="western"><surname>Trebs</surname><given-names>M</given-names></name><name name-style="western"><surname>Kadlecov&#225;</surname><given-names>P</given-names></name><name name-style="western"><surname>Hodisch</surname><given-names>J</given-names></name></person-group><article-title>Bolus application of Landiolol and esmolol: comparison of the Pharmacokinetic and pharmacodynamic profiles in a healthy Caucasian group</article-title><source>Eur J Clin Pharmacol</source><year>2017</year><volume>73</volume><issue>4</issue><fpage>417</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1007/s00228-016-2176-0</pub-id><pub-id pub-id-type="pmid">28091703</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Krumpl G, Ulc I, Trebs M, Kadlecov&#225; P, Hodisch J. Bolus application of Landiolol and esmolol: comparison of the Pharmacokinetic and pharmacodynamic profiles in a healthy Caucasian group. Eur J Clin Pharmacol. 2017;73(4):417&#8211;28.<pub-id pub-id-type="pmid">28091703</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00228-016-2176-0</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><mixed-citation publication-type="other">Bucci T, Proietti R, Lip GYH. Risk of death and thromboembolic events in patients with supraventricular arrhythmias admitted to the emergency department. EP Europace 2024;. Volume 26, Issue Supplement_1, May 2024, euae102.833</mixed-citation></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fornage</surname><given-names>LB</given-names></name><name name-style="western"><surname>Christine</surname><given-names>ON</given-names></name><name name-style="western"><surname>DS</surname><given-names>R</given-names></name><name name-style="western"><surname>WE</surname><given-names>R</given-names></name><name name-style="western"><surname>LR</surname><given-names>S</given-names></name><name name-style="western"><surname>Brown</surname><given-names>LH</given-names></name></person-group><article-title>Prehospital intervention improves outcomes for patients presenting in atrial fibrillation with rapid ventricular response</article-title><source>Prehospital Emerg Care</source><year>2024</year><volume>28</volume><issue>7</issue><fpage>910</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1080/10903127.2023.2283885</pub-id><pub-id pub-id-type="pmid">37975632</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Fornage LB, Christine ON, DS R, WE R, LR S, Brown LH. Prehospital intervention improves outcomes for patients presenting in atrial fibrillation with rapid ventricular response. Prehospital Emerg Care. 2024;28(7):910&#8211;9.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/10903127.2023.2283885</pub-id><pub-id pub-id-type="pmid">37975632</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><mixed-citation publication-type="other">Nasoufidou A, Papazoglou AS, Stachteas P, Karagiannidis E, Samaras A, Alexiou S, Mourtzos MA, Kassimis G, Fragakis N. Intravenous Landiolol for rate control in supraventricular tachyarrhythmias in patients with left ventricular dysfunction: A systematic review and Meta-Analysis. J Clin Med 2024, 13(6).<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/jcm13061683</pub-id><pub-id pub-id-type="pmcid">PMC10971001</pub-id><pub-id pub-id-type="pmid">38541908</pub-id></mixed-citation></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heliste</surname><given-names>M</given-names></name><name name-style="western"><surname>Pettil&#228;</surname><given-names>V</given-names></name><name name-style="western"><surname>Berger</surname><given-names>D</given-names></name><name name-style="western"><surname>Jakob</surname><given-names>SM</given-names></name><name name-style="western"><surname>Wilkman</surname><given-names>E</given-names></name></person-group><article-title>Beta-blocker treatment in the critically ill: a systematic review and meta-analysis</article-title><source>Ann Med</source><year>2022</year><volume>54</volume><issue>1</issue><fpage>1994</fpage><lpage>2010</lpage><pub-id pub-id-type="doi">10.1080/07853890.2022.2098376</pub-id><pub-id pub-id-type="pmid">35838226</pub-id><pub-id pub-id-type="pmcid">PMC9291706</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Heliste M, Pettil&#228; V, Berger D, Jakob SM, Wilkman E. Beta-blocker treatment in the critically ill: a systematic review and meta-analysis. Ann Med. 2022;54(1):1994&#8211;2010.<pub-id pub-id-type="pmid">35838226</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/07853890.2022.2098376</pub-id><pub-id pub-id-type="pmcid">PMC9291706</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><mixed-citation publication-type="other">Whitehouse T, Hossain A, Perkins GD, Gordon AC, Bion J, Young D, McAuley D, Singer M, Lord J, Gates S et al. Landiolol and Organ Failure in Patients With Septic Shock: The STRESS-L Randomized Clinical Trial. <italic toggle="yes">JAMA</italic> 2023.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2023.20134</pub-id><pub-id pub-id-type="pmcid">PMC10600724</pub-id><pub-id pub-id-type="pmid">37877587</pub-id></mixed-citation></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rehberg</surname><given-names>S</given-names></name><name name-style="western"><surname>Frank</surname><given-names>S</given-names></name><name name-style="western"><surname>&#268;ern&#253;</surname><given-names>V</given-names></name><name name-style="western"><surname>Cihl&#225;&#345;</surname><given-names>R</given-names></name><name name-style="western"><surname>Borgstedt</surname><given-names>R</given-names></name><name name-style="western"><surname>Biancofiore</surname><given-names>G</given-names></name><name name-style="western"><surname>Guarracino</surname><given-names>F</given-names></name><name name-style="western"><surname>Schober</surname><given-names>A</given-names></name><name name-style="western"><surname>Trimmel</surname><given-names>H</given-names></name><name name-style="western"><surname>Pernerstorfer</surname><given-names>T</given-names></name><etal/></person-group><article-title>Landiolol for heart rate control in patients with septic shock and persistent tachycardia. A multicenter randomized clinical trial (Landi-SEP)</article-title><source>Intensive Care Med</source><year>2024</year><volume>50</volume><issue>10</issue><fpage>1622</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1007/s00134-024-07587-1</pub-id><pub-id pub-id-type="pmid">39297945</pub-id><pub-id pub-id-type="pmcid">PMC11447033</pub-id></element-citation><mixed-citation id="mc-CR35" publication-type="journal">Rehberg S, Frank S, &#268;ern&#253; V, Cihl&#225;&#345; R, Borgstedt R, Biancofiore G, Guarracino F, Schober A, Trimmel H, Pernerstorfer T, et al. Landiolol for heart rate control in patients with septic shock and persistent tachycardia. A multicenter randomized clinical trial (Landi-SEP). Intensive Care Med. 2024;50(10):1622&#8211;34.<pub-id pub-id-type="pmid">39297945</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00134-024-07587-1</pub-id><pub-id pub-id-type="pmcid">PMC11447033</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schnaubelt</surname><given-names>S</given-names></name><name name-style="western"><surname>Eibensteiner</surname><given-names>F</given-names></name><name name-style="western"><surname>Sulzgruber</surname><given-names>P</given-names></name></person-group><article-title>Landiolol in septic Shock &#8212; No One-Size-Fits-All approach</article-title><source>Heart Lung Circulation</source><year>2024</year><volume>33</volume><issue>4</issue><fpage>e31</fpage><lpage>2</lpage><pub-id pub-id-type="doi">10.1016/j.hlc.2023.12.022</pub-id><pub-id pub-id-type="pmid">38702138</pub-id></element-citation><mixed-citation id="mc-CR36" publication-type="journal">Schnaubelt S, Eibensteiner F, Sulzgruber P. Landiolol in septic Shock &#8212; No One-Size-Fits-All approach. Heart Lung Circulation. 2024;33(4):e31&#8211;2.<pub-id pub-id-type="pmid">38702138</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.hlc.2023.12.022</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hariri</surname><given-names>G</given-names></name><name name-style="western"><surname>Urbina</surname><given-names>T</given-names></name><name name-style="western"><surname>Mazerand</surname><given-names>S</given-names></name><name name-style="western"><surname>Bige</surname><given-names>N</given-names></name><name name-style="western"><surname>Baudel</surname><given-names>JL</given-names></name><name name-style="western"><surname>Ait-Oufella</surname><given-names>H</given-names></name></person-group><article-title>Rate control in atrial fibrillation using Landiolol is safe in critically ill Covid-19 patients</article-title><source>Crit Care</source><year>2021</year><volume>25</volume><issue>1</issue><fpage>33</fpage><pub-id pub-id-type="doi">10.1186/s13054-021-03470-3</pub-id><pub-id pub-id-type="pmid">33482867</pub-id><pub-id pub-id-type="pmcid">PMC7820818</pub-id></element-citation><mixed-citation id="mc-CR37" publication-type="journal">Hariri G, Urbina T, Mazerand S, Bige N, Baudel JL, Ait-Oufella H. Rate control in atrial fibrillation using Landiolol is safe in critically ill Covid-19 patients. Crit Care. 2021;25(1):33.<pub-id pub-id-type="pmid">33482867</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13054-021-03470-3</pub-id><pub-id pub-id-type="pmcid">PMC7820818</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ditali</surname><given-names>V</given-names></name><name name-style="western"><surname>Garatti</surname><given-names>L</given-names></name><name name-style="western"><surname>Morici</surname><given-names>N</given-names></name><name name-style="western"><surname>Villanova</surname><given-names>L</given-names></name><name name-style="western"><surname>Colombo</surname><given-names>C</given-names></name><name name-style="western"><surname>Oliva</surname><given-names>F</given-names></name><name name-style="western"><surname>Sacco</surname><given-names>A</given-names></name></person-group><article-title>Effect of Landiolol in patients with tachyarrhythmias and acute decompensated heart failure (ADHF): a case series</article-title><source>ESC Heart Fail</source><year>2022</year><volume>9</volume><issue>1</issue><fpage>766</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1002/ehf2.13763</pub-id><pub-id pub-id-type="pmid">34962097</pub-id><pub-id pub-id-type="pmcid">PMC8788023</pub-id></element-citation><mixed-citation id="mc-CR38" publication-type="journal">Ditali V, Garatti L, Morici N, Villanova L, Colombo C, Oliva F, Sacco A. Effect of Landiolol in patients with tachyarrhythmias and acute decompensated heart failure (ADHF): a case series. ESC Heart Fail. 2022;9(1):766&#8211;70.<pub-id pub-id-type="pmid">34962097</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ehf2.13763</pub-id><pub-id pub-id-type="pmcid">PMC8788023</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Novotny</surname><given-names>J</given-names></name><name name-style="western"><surname>Klein</surname><given-names>MM</given-names></name><name name-style="western"><surname>Haum</surname><given-names>M</given-names></name><name name-style="western"><surname>Fichtner</surname><given-names>SR</given-names></name><name name-style="western"><surname>Thienel</surname><given-names>MB</given-names></name></person-group><article-title>Prevalence of pathological arrhythmia in patients triaged to cardiac arrhythmia in the emergency department: a preliminary study</article-title><source>Int J Emerg Med</source><year>2022</year><volume>15</volume><issue>1</issue><fpage>49</fpage><pub-id pub-id-type="doi">10.1186/s12245-022-00453-1</pub-id><pub-id pub-id-type="pmid">36100863</pub-id><pub-id pub-id-type="pmcid">PMC9469564</pub-id></element-citation><mixed-citation id="mc-CR39" publication-type="journal">Novotny J, Klein MM, Haum M, Fichtner SR, Thienel MB. Prevalence of pathological arrhythmia in patients triaged to cardiac arrhythmia in the emergency department: a preliminary study. Int J Emerg Med. 2022;15(1):49.<pub-id pub-id-type="pmid">36100863</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12245-022-00453-1</pub-id><pub-id pub-id-type="pmcid">PMC9469564</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>G</given-names></name><name name-style="western"><surname>McD Taylor</surname><given-names>D</given-names></name><name name-style="western"><surname>Morgans</surname><given-names>A</given-names></name><name name-style="western"><surname>Cameron</surname><given-names>P</given-names></name></person-group><article-title>Prehospital management of supraventricular tachycardia in victoria, australia: epidemiology and effectiveness of therapies</article-title><source>Emerg Med Australasia</source><year>2014</year><volume>26</volume><issue>4</issue><fpage>350</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1111/1742-6723.12248</pub-id><pub-id pub-id-type="pmid">24931380</pub-id></element-citation><mixed-citation id="mc-CR40" publication-type="journal">Smith G, McD Taylor D, Morgans A, Cameron P. Prehospital management of supraventricular tachycardia in victoria, australia: epidemiology and effectiveness of therapies. Emerg Med Australasia. 2014;26(4):350&#8211;5.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/1742-6723.12248</pub-id><pub-id pub-id-type="pmid">24931380</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fornage</surname><given-names>LB</given-names></name><name name-style="western"><surname>O&#8217;Neil</surname><given-names>C</given-names></name><name name-style="western"><surname>Dowker</surname><given-names>SR</given-names></name><name name-style="western"><surname>Wanta</surname><given-names>ER</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>RS</given-names></name><name name-style="western"><surname>Brown</surname><given-names>LH</given-names></name></person-group><article-title>Prehospital intervention improves outcomes for patients presenting in atrial fibrillation with rapid ventricular response</article-title><source>Prehospital Emerg Care</source><year>2024</year><volume>28</volume><issue>7</issue><fpage>910</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1080/10903127.2023.2283885</pub-id><pub-id pub-id-type="pmid">37975632</pub-id></element-citation><mixed-citation id="mc-CR41" publication-type="journal">Fornage LB, O&#8217;Neil C, Dowker SR, Wanta ER, Lewis RS, Brown LH. Prehospital intervention improves outcomes for patients presenting in atrial fibrillation with rapid ventricular response. Prehospital Emerg Care. 2024;28(7):910&#8211;9.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/10903127.2023.2283885</pub-id><pub-id pub-id-type="pmid">37975632</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><mixed-citation publication-type="other">Berkenbush M, Sherman N, Jain N, Cosmi P. Prehospital treatment of atrial fibrillation: infusion pump for bolus and infusion? Prehospital Emerg Care:1&#8211;4.2025;29(1):85-88. 10.1080/10903127.2024.2349745. Epub 2024 May 21.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/10903127.2024.2349745</pub-id><pub-id pub-id-type="pmid">38687280</pub-id></mixed-citation></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ball</surname><given-names>J</given-names></name><name name-style="western"><surname>Mahony</surname><given-names>E</given-names></name><name name-style="western"><surname>Nehme</surname><given-names>E</given-names></name><name name-style="western"><surname>Voskoboinik</surname><given-names>A</given-names></name><name name-style="western"><surname>Hogarty</surname><given-names>J</given-names></name><name name-style="western"><surname>Dawson</surname><given-names>LP</given-names></name><name name-style="western"><surname>Horrigan</surname><given-names>M</given-names></name><name name-style="western"><surname>Kaye</surname><given-names>DM</given-names></name><name name-style="western"><surname>Stub</surname><given-names>D</given-names></name><name name-style="western"><surname>Nehme</surname><given-names>Z</given-names></name></person-group><article-title>The burden of atrial fibrillation on emergency medical services: A population-based cohort study</article-title><source>Int J Cardiol</source><year>2024</year><volume>414</volume><fpage>132397</fpage><pub-id pub-id-type="doi">10.1016/j.ijcard.2024.132397</pub-id><pub-id pub-id-type="pmid">39084296</pub-id></element-citation><mixed-citation id="mc-CR43" publication-type="journal">Ball J, Mahony E, Nehme E, Voskoboinik A, Hogarty J, Dawson LP, Horrigan M, Kaye DM, Stub D, Nehme Z. The burden of atrial fibrillation on emergency medical services: A population-based cohort study. Int J Cardiol. 2024;414:132397.<pub-id pub-id-type="pmid">39084296</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijcard.2024.132397</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><mixed-citation publication-type="other">V&#225;squez-Tirado GA, Quispe-Casta&#241;eda CV, Meregildo-Rodr&#237;guez ED, Cuadra-Campos M, Segura-Plasencia NM, Arbayza-Avalos YK, Alva-Guarniz HN, Guzm&#225;n-Aguilar WM, Zavaleta-Alaya P. Association of beta blockers and mortality in adults with septic shock: systematic review and meta-analysis of randomized clinical trial. Front Med 2024;Sep 24:11:1448573; eCollection 2024. <pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fmed.2024.1448573</pub-id><pub-id pub-id-type="pmcid">PMC11458450</pub-id><pub-id pub-id-type="pmid">39380732</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>